Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Hematology›Condition·Updated Jul 11, 2026·v1

Sickle Cell Disease

Sickle cell disease is a common monogenetic disorder with global burden, characterized by HbS polymerization leading to hemolysis, vaso-occlusion, and progressive organ damage. Management includes hydroxyurea as first-line disease-modifying therapy, targeted agents (voxelotor, mitapivat, L-glutamine) for refractory cases, and curative options (HSCT, gene therapy) for severe disease. Systematic screening for stroke, nephropathy, pulmonary hypertension, and retinopathy is essential. Prognosis has improved in high-resource settings but remains poor in sub-Saharan Africa without early intervention.

High Evidence440 references·10,558 words·43 min read·v1
sickle cell diseasehemoglobinopathyvaso-occlusive crisishematologypediatricstransfusion medicinegene therapy

Quick Reference

RxDrug of choiceHydroxyurea (15-20 mg/kg/day, titrate to MTD)
AltAlternativesVoxelotor 1500 mg daily, Mitapivat 50-100 mg BID, L-glutamine 0.3 g/kg BID
⊘AvoidMeperidine (seizure risk), Ticagrelor (no benefit), Crizanlizumab (negative STAND trial), non-dihydropyridine CCBs (exacerbate heart failure)
DxTest of choiceHemoglobin electrophoresis or HPLC for diagnosis; TCD ultrasound for stroke screening in children
ScKey scorePhenotypic risk score (Sachdev), predicts 4-year mortality using TRV, echocardiographic parameters, BMI, BUN, alkaline phosphatase, heart rate, age
→When to referRecurrent VOC despite hydroxyurea, acute chest syndrome, stroke, priapism, progressive organ damage, consideration for HSCT/gene therapy
Early diagnosis via newborn screening, hydroxyurea as first-line disease-modifying therapy, and systematic surveillance for end-organ damage reduce morbidity and mortality; curative options (HSCT, gene therapy) should be discussed early for severe disease.
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a point mutation in the β-globin gene (Glu6Val) that produces hemoglobin S (HbS), which polymerizes under deoxygenation, leading to chronic hemolytic anemia, recurrent vaso-occlusive events, and progressive multi-organ damage. With an estimated 7.74 million people affected worldwide and 515,000 affected births annually, SCD imposes a substantial global burden, particularly in sub-Saharan Africa where under-5 mortality can exceed 50% without intervention. Management has evolved from supportive care to disease-modifying therapies (hydroxyurea, voxelotor, mitapivat) and curative options (hematopoietic stem cell transplantation, gene therapy). Early diagnosis through newborn screening, infection prophylaxis, and systematic surveillance for end-organ damage are critical to improving outcomes.

Overview and Recommendations

Background

  • •Sickle cell disease (SCD) is a monogenetic disorder caused by a single nucleotide substitution (GAG→GTG) at codon 6 of the β-globin gene, replacing glutamic acid with valine to produce hemoglobin S (HbS). Under deoxygenation, HbS polymerizes, distorting erythrocytes into the classic sickle shape and initiating a self-perpetuating cycle of hemolysis, inflammation, and vaso-occlusion that progressively damages every organ system.
  • •SCD affects approximately 7.74 million people globally, with 515,000 affected births annually, a 13.7% increase since 2000 driven by population growth in sub-Saharan Africa and the Caribbean. Over 75% of affected births occur in sub-Saharan Africa, where without newborn screening and comprehensive care, 50-90% of children die before age 5. In high-resource settings, median age at death for adults with SCD and chronic kidney disease is only 53 years.
  • •The three most common genotypes, HbSS (homozygous), HbSC (compound heterozygote with HbC), and HbSβ-thalassemia, account for 98.5% of SCD cases. HbSS and HbSβ⁰-thalassemia are typically severe, while HbSC and HbSβ⁺-thalassemia follow a milder course. Genetic modifiers such as elevated fetal hemoglobin (HbF) and co-inherited α-thalassemia reduce disease severity, while variants in BCL11A and HBS1L-MYB modulate HbF levels.
  • •Vaso-occlusion is a multicellular thromboinflammatory cascade: dense sickled cells adhere to venular endothelium via receptors like Lu/BCAM, P-selectin upregulation mediates leukocyte and sickled cell adhesion, and von Willebrand factor becomes hyperadhesive. Hemolysis releases cell-free hemoglobin and heme, which activate Toll-like receptor 4 and the cGAS-STING pathway, promoting neutrophil extracellular trap formation and coagulation activation. This chronic inflammation drives progressive fibrosis in kidneys, lungs, liver, and heart.
  • •The paradigm shift in management began with hydroxyurea (FDA-approved 1998) and accelerated with targeted therapies (voxelotor, mitapivat, L-glutamine) and curative cellular therapies (hematopoietic stem cell transplantation, exagamglogene autotemcel). The four pillars of modern disease-modifying therapy, hydroxyurea, voxelotor, mitapivat, and L-glutamine, target HbS polymerization, hemolysis, and oxidative stress, while P-selectin inhibition (crizanlizumab) showed mixed results.

Evaluation

  • •Suspect SCD in any patient with episodic severe pain (vaso-occlusive crisis), chronic hemolytic anemia, or a family history of hemoglobinopathy. Typical presenting symptoms include bone pain, chest pain, abdominal pain, or back pain, often triggered by cold, infection, dehydration, or stress. Ask about prior complications: acute chest syndrome, stroke, priapism, leg ulcers, or splenic sequestration.
  • •Examine for pallor, jaundice, scleral icterus, and splenomegaly (in children; adults often have functional asplenia). Look for leg ulcers (typically over medial malleoli), retinopathy on fundoscopy, and signs of pulmonary hypertension (loud P2, right ventricular heave). In children, assess growth parameters and neurodevelopmental milestones.
  • •Order a complete blood count with reticulocyte count, typical findings: hemoglobin 6-9 g/dL, elevated reticulocytes (3-15%), and elevated mean corpuscular hemoglobin concentration. Peripheral blood smear may show sickle cells, target cells, Howell-Jolly bodies (functional asplenia), and nucleated red blood cells. A normal smear does not exclude SCD.
  • •Definitive diagnosis requires hemoglobin analysis by high-performance liquid chromatography (HPLC), isoelectric focusing, or capillary electrophoresis. HbS >50% with another β-globin variant (HbC, β-thalassemia) confirms SCD. Molecular genotyping (PCR/sequencing) is the gold standard for equivocal cases, prenatal diagnosis, or identifying coinherited modifiers like α-thalassemia.
  • •In children with HbSS or HbSβ⁰-thalassemia, perform annual transcranial Doppler (TCD) ultrasound from age 2 to at least 16 years to screen for stroke risk. Abnormal TCD velocity >200 cm/s warrants chronic transfusion or hydroxyurea. A single brain MRI without sedation is recommended at least once in childhood and once in adulthood to detect silent cerebral infarcts.
  • •Screen for end-organ damage annually: urine albumin-to-creatinine ratio and estimated glomerular filtration rate for nephropathy; echocardiography with tricuspid regurgitant jet velocity (TRV) every 1-3 years starting in adolescence for pulmonary hypertension; dilated fundus examination yearly for high-risk patients (older HbSC males, low HbF) and triennially for low-risk patients.
  • •Evaluate for acute complications: in a patient with acute pain, fever, and respiratory symptoms, obtain chest X-ray and pulse oximetry to rule out acute chest syndrome (new pulmonary infiltrate plus respiratory symptoms). In recently transfused patients with pain, fever, and falling hemoglobin, suspect delayed hemolytic transfusion reaction (DHTR), check hemoglobin, LDH, reticulocyte count; reticulocytopenia is a red flag.
  • •Assess for venous thromboembolism: SCD carries a 5.2 events/1000 person-years incidence of VTE, with pulmonary embolism disproportionately common. Consider D-dimer and CT pulmonary angiography if clinically indicated. Also evaluate for priapism in males: ask about sustained painful erections >4 hours.
  • •Consider bone marrow examination only for specific indications: aplastic crisis (parvovirus B19, shows erythroid hypoplasia with giant pronormoblasts), unexplained cytopenias, or pre-transplant assessment. Routine marrow is not needed for diagnosis.
  • •Use validated prognostic scores to stratify risk: the phenotypic risk score (Sachdev) uses TRV, estimated right atrial pressure, mitral E velocity, left ventricular septal thickness, BMI, BUN, alkaline phosphatase, heart rate, and age to predict 4-year mortality (3% to 75%). The hemolytic component (reticulocyte count, LDH, AST, total bilirubin) independently predicts mortality (HR 3.44).

Management

  • •Initiate hydroxyurea as first-line disease-modifying therapy for patients with frequent vaso-occlusive crises (≥2 per year), acute chest syndrome, or symptomatic anemia. Start at 15-20 mg/kg/day orally, escalate every 8 weeks to maximum tolerated dose (MTD) defined by mild myelosuppression (absolute neutrophil count 2000-4000/μL) or plateau in HbF response. Target HbF ≥20%.
  • •Monitor hydroxyurea adherence with blood levels or mean corpuscular volume (MCV), undetectable drug levels occur in 61% of patients ≥10 years and 76% of those <10 years, correlating with lower MCV and HbF. Adjust dosing accordingly.
  • •For patients with inadequate response to hydroxyurea (persistent VOC or anemia), add or switch to novel oral agents: voxelotor 1500 mg orally once daily for anemia (Hb response 51% vs 7%, NNT=2.3); mitapivat 50-100 mg twice daily for hemolysis and VOC (Hb response 46-50%, NNT≈2.2); L-glutamine 0.3 g/kg/dose twice daily for oxidative stress (median 1 fewer crisis per 48 weeks).
  • •Do not prescribe crizanlizumab as first- or second-line therapy, the phase 3 STAND trial showed no significant reduction in annualized VOC rates (2.49 vs 2.30 with placebo) and higher grade ≥3 adverse events (56% vs 32%). Discuss conflicting SUSTAIN and STAND results if considering.
  • •For acute vaso-occlusive crisis, administer parenteral opioids within 30 minutes of triage: morphine 0.1-0.15 mg/kg IV or hydromorphone 0.015-0.02 mg/kg IV. Reassess pain every 15-30 minutes; escalate dose by 25-50% or initiate patient-controlled analgesia if severe. Avoid meperidine due to seizure risk. Use intranasal fentanyl 1.5 mcg/kg as bridging if no IV access.
  • •For acute chest syndrome, provide supplemental oxygen to maintain SaO₂ ≥95%, bronchodilators if wheezing, and empiric broad-spectrum antibiotics (macrolide + third-generation cephalosporin). Use incentive spirometry (10 breaths every 2 hours while awake) to reduce progression. For hemoglobin ≤9 g/dL or rapid fall, give simple transfusion 10 mL/kg packed red cells; for severe or worsening ACS, perform exchange transfusion. Transfer to ICU if SaO₂/FiO₂ ratio <310.
  • •For acute ischemic stroke, obtain emergency neuroimaging and initiate acute red cell exchange as soon as possible (target HbS <30%). Thrombolysis is rarely used due to frequent ineligibility. For priapism lasting <4 hours, perform intracavernosal aspiration and irrigation with or without phenylephrine; for stuttering priapism, consider sildenafil prophylaxis.
  • •For transfusion support, use ABO/Rh (D, C, c, E, e) and Kell-matched red cells for all patients to reduce alloimmunization. Avoid transfusion during proinflammatory events when possible (alloimmunization risk increases 4-fold). For chronic transfusion (e.g., stroke prevention), maintain HbS <30% using simple transfusion or erythrocytapheresis. Start iron chelation when serum ferritin >1000 ng/mL or liver iron >5 mg/g dry weight: deferasirox 20-40 mg/kg/day, deferiprone 75-100 mg/kg/day, or deferoxamine.
  • •Provide infection prophylaxis: daily oral penicillin from diagnosis until at least age 5; pneumococcal vaccination with PCV13 in infancy and PPSV23 starting at age 2; annual influenza vaccine; meningococcal and Haemophilus influenzae type b vaccines. In malaria-endemic areas, provide malaria prophylaxis.
  • •Refer for curative therapy (hematopoietic stem cell transplantation or gene therapy) in patients with severe disease: recurrent VOC despite optimized medical therapy, stroke, progressive organ damage, or recurrent acute chest syndrome. For children with an HLA-matched sibling donor, myeloablative HSCT offers >95% event-free survival. For patients without a matched sibling, discuss haploidentical HSCT with post-transplant cyclophosphamide or autologous gene therapy (exagamglogene autotemcel, lovotibeglogene autotemcel).
  • •Discharge criteria for acute VOC: pain controlled on oral analgesics, no hypoxia (SaO₂ ≥95% on room air), stable hemoglobin (within 1 g/dL of baseline), no fever, ability to tolerate oral intake, and follow-up arranged within 1-2 weeks. Ensure hydroxyurea adherence and provide written crisis action plan.

Board Review — High Yield

  • •HbS polymerization, The root cause of SCD; triggered by deoxygenation, inhibited by fetal hemoglobin (HbF) >15-20%.
  • •P-selectin, Endothelial adhesion molecule targeted by crizanlizumab; SUSTAIN trial showed 45% VOC reduction, but STAND trial failed to confirm.
  • •Transcranial Doppler (TCD), Annual screening in children age 2-16; velocity >200 cm/s indicates high stroke risk and need for chronic transfusion.
  • •Acute chest syndrome, New pulmonary infiltrate + respiratory symptoms; treat with antibiotics, incentive spirometry, and exchange transfusion if severe.
  • •Delayed hemolytic transfusion reaction (DHTR), Suspect when hemoglobin drops 5-14 days post-transfusion with pain and fever; reticulocytopenia is a red flag; avoid further transfusion unless absolutely necessary.
  • •Hydroxyurea maximum tolerated dose (MTD), Defined by mild myelosuppression (ANC 2000-4000/μL); target HbF ≥20%.
  • •Exagamglogene autotemcel (exa-cel), CRISPR-Cas9 gene therapy targeting BCL11A; 97% freedom from severe VOC at 12 months in CLIMB SCD-121 trial.
  • •Phenotypic risk score, Composite of 9 variables (including TRV, BUN, age) stratifies 4-year mortality from 3% to 75%.
  • •Sickle cell nephropathy, Screen with urine ACR annually; ACE inhibitors for albuminuria; distinct pathophysiology from APOL1-mediated disease.
  • •Functional asplenia, Present in most adults with HbSS; requires penicillin prophylaxis and vaccination against encapsulated organisms.

Deep Dive — Evidence Details

References

  1. [1]

    Kwiatkowski JL, Granger S, Brambilla DJ et al.. “Elevated blood flow velocity in the anterior cerebral artery and stroke risk in sickle cell disease: extended analysis from the STOP trial.” British journal of haematology (2006). PMID: 16848777 ↗

    L2RCTCited in: 1. Definition, Classification & Nomenclature
  2. [2]

    Pimenta K, Edwards J, Ray M et al.. “Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis.” British journal of haematology (2026). PMID: 42070793 ↗

    L1SR_OBSCited in: 1. Definition, Classification & Nomenclature, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  3. [3]

    Ali SB, Reid M, Fraser R et al.. “Seizures in the Jamaica cohort study of sickle cell disease.” British journal of haematology (2010). PMID: 20813003 ↗

    L2COHORTCited in: 1. Definition, Classification & Nomenclature
  4. [4]

    Locatelli F, Kabbara N, Ruggeri A et al.. “Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling.” Blood (2013). PMID: 23692854 ↗

    L2OTHERCited in: 1. Definition, Classification & Nomenclature, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  5. [5]

    . “Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021.” The Lancet. Haematology (2023). PMID: 37331373 ↗

    L2OTHERCited in: 1. Definition, Classification & Nomenclature, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  6. [6]

    Aurora T, Hodges R, Wardell JR et al.. “A novel US-based grading system for disease severity in sickle cell disease: the Sickle Cell Outcome Grading System (SCOGS).” The Lancet. Haematology (2026). PMID: 42242263 ↗

    L5REVIEW_NARRATIVECited in: 1. Definition, Classification & Nomenclature
  7. [7]

    Grazioli A, Plazak M, Willsey K et al.. “Outcomes and survival prediction in adults with sickle cell disease treated with extracorporeal membrane oxygenation.” Blood advances (2025). PMID: 40644625 ↗

    L2OTHERCited in: 1. Definition, Classification & Nomenclature, 3. Epidemiology, Etiology & Risk Factors, 7. Acute & Emergency Management
  8. [8]

    Jenkins AM, Hendry E, Power-Hays A et al.. “Increasing ketamine administration in children's hospitals for youth with sickle cell disease.” Blood advances (2026). PMID: 41337693 ↗

    L4OTHERCited in: 1. Definition, Classification & Nomenclature
  9. [9]

    Srisuwananukorn A, Raslan R, Zhang X et al.. “Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease.” Blood advances (2020). PMID: 32384541 ↗

    L2OTHERCited in: 1. Definition, Classification & Nomenclature
  10. [10]

    Kumar R, Stanek J, Creary S et al.. “Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study.” Blood advances (2018). PMID: 29431623 ↗

    L2OTHERCited in: 1. Definition, Classification & Nomenclature
  11. [11]

    Wuichet K, Corty R, Bick A et al.. “Accurate identification of sickle cell disease cases in a large genotyped cohort using electronic health record data.” Blood advances (2026). PMID: 41921205 ↗

    L2OTHERCited in: 1. Definition, Classification & Nomenclature
  12. [12]

    Kaweme NM, Buttress SMN, Nguweneza A et al.. “Burden and outcomes of cardiovascular and pulmonary complications in adolescents and adults with sickle cell disease: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 41673762 ↗

    L1SR_OBSCited in: 1. Definition, Classification & Nomenclature, 3. Epidemiology, Etiology & Risk Factors
  13. [13]

    Ericksen PN, Dabbous F, Ghosh R et al.. “Standardization of coding definitions for sickle cell disease complications: A systematic literature review.” Pharmacoepidemiology and drug safety (2024). PMID: 39205482 ↗

    L1SR_OBSCited in: 1. Definition, Classification & Nomenclature
  14. [14]

    Kaufmann GT, Russell M, Shukla P et al.. “Retrospective Cohort Study of Sickle Cell Disease and Large Vessel Retinal Vascular Occlusion Risk in a National United States Database.” Ophthalmology. Retina (2024). PMID: 39033926 ↗

    L2COHORTCited in: 1. Definition, Classification & Nomenclature
  15. [15]

    Valle J, Lebensburger JD, Garimella PS et al.. “Prevalence, Mortality, and Access to Care for Chronic Kidney Disease in Medicaid-Enrolled Adults With Sickle Cell Disease in California: Retrospective Cohort Study.” JMIR public health and surveillance (2024). PMID: 39008353 ↗

    L2COHORTCited in: 1. Definition, Classification & Nomenclature
  16. [16]

    Jose A, Bodade A, Madkaikar MR. “Assessing and managing iron deficiency anemia in sickle cell disease: Insights from a systematic review and meta-analysis.” Journal of postgraduate medicine (2025). PMID: 40047486 ↗

    L1SR_OBSCited in: 1. Definition, Classification & Nomenclature
  17. [17]

    Niihara Y, Miller ST, Kanter J et al.. “A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.” The New England journal of medicine (2018). PMID: 30021096 ↗

    L1RCTCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  18. [18]

    Ataga KI, Kutlar A, Kanter J et al.. “Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.” The New England journal of medicine (2016). PMID: 27959701 ↗

    L1RCTCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  19. [19]

    Vichinsky E, Hoppe CC, Ataga KI et al.. “A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.” The New England journal of medicine (2019). PMID: 31199090 ↗

    L1RCTCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, History and Evolution of Treatment
  20. [20]

    Tumburu L, Ghosh-Choudhary S, Seifuddin FT et al.. “Circulating mitochondrial DNA is a proinflammatory DAMP in sickle cell disease.” Blood (2021). PMID: 33661274 ↗

    L3TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring
  21. [21]

    Garrett ME, Soldano KL, Erwin KN et al.. “Genome-wide meta-analysis identifies new candidate genes for sickle cell disease nephropathy.” Blood advances (2023). PMID: 36399516 ↗

    L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 11. Complications, 12. Prognosis & Natural History
  22. [22]

    Olujohungbe A, Burnett AL. “How I manage priapism due to sickle cell disease.” British journal of haematology (2013). PMID: 23293942 ↗

    L5TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism, 7. Acute & Emergency Management, 11. Complications, 12. Prognosis & Natural History
  23. [23]

    Ribeil JA, Hacein-Bey-Abina S, Payen E et al.. “Gene Therapy in a Patient with Sickle Cell Disease.” The New England journal of medicine (2017). PMID: 28249145 ↗

    L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  24. [24]

    Steinberg MH. “Fetal hemoglobin in sickle cell anemia.” Blood (2020). PMID: 32808012 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management
  25. [25]

    Atiq F, O'Donnell JS. “Novel functions for von Willebrand factor.” Blood (2024). PMID: 38728426 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  26. [26]

    Li C, Georgakopoulou A, Newby GA et al.. “In vivo HSC prime editing rescues sickle cell disease in a mouse model.” Blood (2023). PMID: 36800642 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management
  27. [27]

    Byrnes JR, Wolberg AS. “Red blood cells in thrombosis.” Blood (2017). PMID: 28811305 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  28. [28]

    Pinto VM, Mazzi F, De Franceschi L. “Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders.” Blood (2024). PMID: 38820588 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  29. [29]

    Sharma R, Antypiuk A, Vance SZ et al.. “Macrophage metabolic rewiring improves heme-suppressed efferocytosis and tissue damage in sickle cell disease.” Blood (2023). PMID: 36952641 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism
  30. [30]

    Han Y, Gao C, Liu Y et al.. “Hemolysis-driven IFNα production impairs erythropoiesis by negatively regulating EPO signaling in sickle cell disease.” Blood (2024). PMID: 38127913 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  31. [31]

    Esoh K, Wonkam-Tingang E, Wonkam A. “Sickle cell disease in sub-Saharan Africa: transferable strategies for prevention and care.” The Lancet. Haematology (2021). PMID: 34481550 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  32. [32]

    Grunenwald A, Peliconi J, Zarantonello A et al.. “HCAR2 is a novel receptor for heme.” Blood advances (2025). PMID: 40353812 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 14. Prevention, Screening & Surveillance
  33. [33]

    Dosunmu-Ogunbi AM, Wood KC, Novelli EM et al.. “Decoding the role of SOD2 in sickle cell disease.” Blood advances (2019). PMID: 31506286 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  34. [34]

    Adebiyi MG, Manalo JM, Xia Y. “Metabolomic and molecular insights into sickle cell disease and innovative therapies.” Blood advances (2019). PMID: 31015210 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  35. [35]

    Williams DA, Esrick E. “Investigational curative gene therapy approaches to sickle cell disease.” Blood advances (2021). PMID: 34905048 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  36. [36]

    Lucero MJ, Setua S, Thangaraju K et al.. “Ferroportin inhibition attenuates pulmonary hypertension in hypoxic sickle cell disease mice.” Blood advances (2026). PMID: 41538305 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  37. [37]

    Lê BM, Hatch D, Yang Q et al.. “Characterizing epigenetic aging in an adult sickle cell disease cohort.” Blood advances (2024). PMID: 37967379 ↗

    L4OTHERCited in: 2. Pathophysiology & Mechanism
  38. [38]

    Costa E, Isgrò A, de Montalembert M et al.. “Successes and pitfalls in orphan drug development for sickle cell disease.” Blood advances (2024). PMID: 38522095 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  39. [39]

    Rees DC, Williams TN, Gladwin MT. “Sickle-cell disease.” Lancet (London, England) (2010). PMID: 21131035 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  40. [40]

    Ware RE, de Montalembert M, Tshilolo L et al.. “Sickle cell disease.” Lancet (London, England) (2017). PMID: 28159390 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 4. Clinical Presentation, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  41. [41]

    Colombatti R, Jastaniah W, Makani J et al.. “Sickle cell disease.” Lancet (London, England) (2026). PMID: 41831848 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  42. [42]

    Gladwin MT. “Cardiovascular complications and risk of death in sickle-cell disease.” Lancet (London, England) (2016). PMID: 27353687 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  43. [43]

    Carden MA, Little J. “Emerging disease-modifying therapies for sickle cell disease.” Haematologica (2019). PMID: 31413089 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  44. [44]

    Saunthararajah Y. “Targeting sickle cell disease root-cause pathophysiology with small molecules.” Haematologica (2019). PMID: 31399526 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  45. [45]

    Allali S, Maciel TT, Hermine O et al.. “Innate immune cells, major protagonists of sickle cell disease pathophysiology.” Haematologica (2020). PMID: 31919091 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  46. [46]

    Conran N, De Paula EV. “Thromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance.” Haematologica (2020). PMID: 33054078 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  47. [47]

    Lizarralde-Iragorri MA, Lefevre SD, Cochet S et al.. “Oxidative stress activates red cell adhesion to laminin in sickle cell disease.” Haematologica (2021). PMID: 32855277 ↗

    L3OTHERCited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  48. [48]

    Brandsen RP, Diederen RMH, Kocabas G et al.. “Clinical and laboratory risk factors for sickle cell retinopathy and maculopathy: a scoping review of the current evidence.” Haematologica (2024). PMID: 39704162 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 14. Prevention, Screening & Surveillance
  49. [49]

    Kaminski TW, Katoch O, Li Z et al.. “Impaired hemoglobin clearance by sinusoidal endothelium promotes vaso-occlusion and liver injury in sickle cell disease.” Haematologica (2024). PMID: 37941440 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism
  50. [50]

    Schimmel M, Nur E, Biemond BJ et al.. “Nucleosomes and neutrophil activation in sickle cell disease painful crisis.” Haematologica (2013). PMID: 23911704 ↗

    L2OTHERCited in: 2. Pathophysiology & Mechanism
  51. [51]

    Pace BS, Starlard-Davenport A, Kutlar A. “Sickle cell disease: progress towards combination drug therapy.” British journal of haematology (2021). PMID: 33471938 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  52. [52]

    Rees DC, Gibson JS. “Biomarkers in sickle cell disease.” British journal of haematology (2011). PMID: 22122125 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 6. Staging, Risk Stratification & Prognostic Scoring
  53. [53]

    Paikari A, Sheehan VA. “Fetal haemoglobin induction in sickle cell disease.” British journal of haematology (2017). PMID: 29143315 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  54. [54]

    Gupta CL, Jaganathasamy N, Madkaikar M. “Microbiome in sickle cell disease: Pathophysiology and therapeutic insights.” British journal of haematology (2024). PMID: 39206530 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  55. [55]

    Piccin A, O'Connor-Byrne N, Daves M et al.. “Autoimmune disease and sickle cell anaemia: 'Intersecting pathways and differential diagnosis'.” British journal of haematology (2022). PMID: 35244209 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management
  56. [56]

    Wilson S, Ellsworth P, Key NS. “Pregnancy in sickle cell trait: what we do and don't know.” British journal of haematology (2020). PMID: 32064587 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 13. Special Populations & Pregnancy
  57. [57]

    Catella J, Guillot N, Nader E et al.. “Controversies in the pathophysiology of leg ulcers in sickle cell disease.” British journal of haematology (2024). PMID: 38867511 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  58. [58]

    Sparkenbaugh E, Pawlinski R. “Prothrombotic aspects of sickle cell disease.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28671346 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  59. [59]

    Sparkenbaugh EM, Kasztan M, Henderson MW et al.. “High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32573897 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History
  60. [60]

    Sins JWR, Schimmel M, Luken BM et al.. “Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.” Journal of thrombosis and haemostasis : JTH (2017). PMID: 28457019 ↗

    L2OTHERCited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  61. [61]

    Al-Subaie AM, Borgio JF. “Systematic Review of Non-Coding Genomic Variants in Globin and Non-Globin Clusters and Their Impact on Phenotypic Severity in Thalassemia and Sickle Cell Disease.” Journal of clinical medicine (2026). PMID: 41753033 ↗

    L5SR_OBSCited in: 2. Pathophysiology & Mechanism, 4. Clinical Presentation, 6. Staging, Risk Stratification & Prognostic Scoring
  62. [62]

    Simo JL, Tuono RM, Yong IWS et al.. “Complete Blood Count Profile in Steady State Sickle Cell Disease Patient: A Systematic Review and Meta-Analysis.” Health science reports (2026). PMID: 42022594 ↗

    L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  63. [63]

    Simo JL, Tuono RM, Njopwouo MS et al.. “Oxidative Stress, Antioxidant Capacity, Dyslipidemia and Cardiovascular Risk in Sickle Cell Disease: A Systematic Review and Meta-Analysis.” TheScientificWorldJournal (2026). PMID: 41821306 ↗

    L2SR_OBSCited in: 2. Pathophysiology & Mechanism
  64. [64]

    Simo JL, Angandji PT, Tuono RM et al.. “Hepatic Enzyme Abnormalities and Their Association With Hematological Parameters in Sickle Cell Disease: A Case-Control Study in Cameroon.” Health science reports (2026). PMID: 42291724 ↗

    L3CASE_CONTROLCited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  65. [65]

    Wood KC, Nouraie SM, Gladwin MT et al.. “The CYB5R3 T117S Missense Variant is Associated with Attenuated Riociguat Efficacy in Sickle Cell Disease.” Blood (2026). PMID: 42418684 ↗

    L2OTHERCited in: 2. Pathophysiology & Mechanism
  66. [66]

    Martin OY, Darbari DS. “Pain in SCD-Many mechanisms and mysteries.” Seminars in hematology (2026). PMID: 42392892 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management
  67. [67]

    Weeks LD. “Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.” Seminars in hematology (2026). PMID: 42373375 ↗

    L5OTHERCited in: 2. Pathophysiology & Mechanism
  68. [68]

    Sufian S. “Menopause in rare diseases: Shared research concerns and the case for a dedicated subfield.” Maturitas (2026). PMID: 42308878 ↗

    L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism
  69. [69]

    Heeney MM, Abboud MR, Githanga J et al.. “Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study.” Blood (2022). PMID: 35849650 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 7. Acute & Emergency Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 13. Special Populations & Pregnancy
  70. [70]

    Abboud MR, Cançado RD, De Montalembert M et al.. “Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.” The Lancet. Haematology (2025). PMID: 40088922 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, History and Evolution of Treatment
  71. [71]

    Howard J, Ataga KI, Brown RC et al.. “Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet. Haematology (2021). PMID: 33838113 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  72. [72]

    Austin H, Key NS, Benson JM et al.. “Sickle cell trait and the risk of venous thromboembolism among blacks.” Blood (2007). PMID: 17409269 ↗

    L3TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors
  73. [73]

    Yuditskaya S, Tumblin A, Hoehn GT et al.. “Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease.” Blood (2008). PMID: 19023114 ↗

    L3TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors
  74. [74]

    Shenoy S, Eapen M, Panepinto JA et al.. “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.” Blood (2016). PMID: 27625358 ↗

    L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  75. [75]

    Oteng-Ntim E, Oakley LL, Robinson V et al.. “Prophylactic exchange transfusion in sickle cell disease pregnancy: a TAPS2 feasibility randomized controlled trial.” Blood advances (2024). PMID: 38954844 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 13. Special Populations & Pregnancy
  76. [76]

    Goldenberg M, Varadhan R, Gamper CJ et al.. “Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI.” Blood advances (2026). PMID: 41569644 ↗

    L4TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications, 12. Prognosis & Natural History
  77. [77]

    Parikh S, Brochstein JA, Galamidi E et al.. “Allogeneic stem cell transplantation with omidubicel in sickle cell disease.” Blood advances (2021). PMID: 33560399 ↗

    L4TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 13. Special Populations & Pregnancy
  78. [78]

    Lamarre Y, Romana M, Waltz X et al.. “Hemorheological risk factors of acute chest syndrome and painful vaso-occlusive crisis in children with sickle cell disease.” Haematologica (2012). PMID: 22689686 ↗

    L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  79. [79]

    Jacobs JW, Stephens LD, Allen ES et al.. “Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review.” British journal of haematology (2023). PMID: 37074146 ↗

    L4SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  80. [80]

    Shet AS, Wun T. “How I diagnose and treat venous thromboembolism in sickle cell disease.” Blood (2018). PMID: 29764840 ↗

    L5CASE_REPORTCited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 6. Staging, Risk Stratification & Prognostic Scoring
  81. [81]

    Scott JA, Berkley JA, Mwangi I et al.. “Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study.” Lancet (London, England) (2011). PMID: 21903251 ↗

    L3CASE_CONTROLCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications
  82. [82]

    Novelli EM, Huynh C, Gladwin MT et al.. “Pulmonary embolism in sickle cell disease: a case-control study.” Journal of thrombosis and haemostasis : JTH (2012). PMID: 22417249 ↗

    L3CASE_CONTROLCited in: 3. Epidemiology, Etiology & Risk Factors, 12. Prognosis & Natural History
  83. [83]

    Smith-Whitley K. “Reproductive issues in sickle cell disease.” Blood (2014). PMID: 25472967 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  84. [84]

    Pecker LH, Naik RP. “The current state of sickle cell trait: implications for reproductive and genetic counseling.” Blood (2018). PMID: 30487130 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 14. Prevention, Screening & Surveillance
  85. [85]

    Piel FB, Rees DC, DeBaun MR et al.. “Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.” The Lancet. Haematology (2023). PMID: 37451304 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  86. [86]

    Mañú Pereira MDM, Colombatti R, Alvarez F et al.. “Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspective.” The Lancet. Haematology (2023). PMID: 37451300 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors
  87. [87]

    Allen ES, Srivastava K, Hsieh MM et al.. “Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study.” The Lancet. Haematology (2017). PMID: 29100558 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  88. [88]

    DeBaun MR, Strunk RC. “The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia.” Lancet (London, England) (2016). PMID: 27353685 ↗

    L5CASE_REPORTCited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation
  89. [89]

    Dorfman SR, Chan SS, Amanullah S et al.. “ACR Appropriateness Criteria® Chest Pain-Child.” Journal of the American College of Radiology : JACR (2026). PMID: 41729147 ↗

    L1GUIDELINECited in: 3. Epidemiology, Etiology & Risk Factors, 7. Acute & Emergency Management, History and Evolution of Treatment
  90. [90]

    Eapen M, Brazauskas R, Williams DA et al.. “Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36623245 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  91. [91]

    Sinha U, Setty S, Pilon C et al.. “Systemic lupus erythematosus-associated autoantibodies in sickle cell disease: Spontaneous emergence in a patient and in transgenic sickle mice.” British journal of haematology (2025). PMID: 39748216 ↗

    L4CASE_REPORTCited in: 3. Epidemiology, Etiology & Risk Factors
  92. [92]

    Patwardhan AA, Patel A, Pasupuleti A et al.. “Use of the microfluidic impedance red cell assay in sickle cell disease.” Blood advances (2025). PMID: 40311069 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  93. [93]

    Kumari N, Ammosova T, Diaz S et al.. “Increased iron export by ferroportin induces restriction of HIV-1 infection in sickle cell disease.” Blood advances (2016). PMID: 28203649 ↗

    L5OTHERCited in: 3. Epidemiology, Etiology & Risk Factors
  94. [94]

    Schoettler M, Stenger E, Spencer K et al.. “Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children.” Blood advances (2023). PMID: 36075028 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 14. Prevention, Screening & Surveillance
  95. [95]

    Lettre G, Bauer DE. “Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies.” Lancet (London, England) (2016). PMID: 27353686 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management
  96. [96]

    Afolabi BB, Babah OA, Oshodi YA et al.. “Low-dose aspirin for preventing intrauterine growth restriction and pre-eclampsia in sickle cell pregnancy in Nigeria (PIPSICKLE): a randomised controlled trial.” The Lancet. Global health (2026). PMID: 41713441 ↗

    L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  97. [97]

    Brousse V, Bernaudin F, Melaine A et al.. “Severity and burden of sickle cell disease in France: a nationwide real-world study.” Haematologica (2023). PMID: 36924235 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  98. [98]

    Linguet SL, Verlhac S, Missud F et al.. “Stroke without cerebral arteriopathy in sickle cell disease children: causes and treatment.” Haematologica (2024). PMID: 38497171 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  99. [99]

    Day TG, Drasar ER, Fulford T et al.. “Association between hemolysis and albuminuria in adults with sickle cell anemia.” Haematologica (2011). PMID: 21993677 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors
  100. [100]

    Evans C, Orf K, Horvath E et al.. “Impairment of neutrophil oxidative burst in children with sickle cell disease is associated with heme oxygenase-1.” Haematologica (2015). PMID: 26315932 ↗

    L3OTHERCited in: 3. Epidemiology, Etiology & Risk Factors
  101. [101]

    Nouraie M, Lee JS, Zhang Y et al.. “The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe.” Haematologica (2012). PMID: 22983573 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring
  102. [102]

    Chaar V, Picot J, Renaud O et al.. “Aggregation of mononuclear and red blood cells through an {alpha}4{beta}1-Lu/basal cell adhesion molecule interaction in sickle cell disease.” Haematologica (2010). PMID: 20562314 ↗

    L3OTHERCited in: 3. Epidemiology, Etiology & Risk Factors
  103. [103]

    Loh J, Kuo KHM, Georgescu I et al.. “Risk factors for immediate postpartum sickle cell disease-specific maternal morbidity.” British journal of haematology (2025). PMID: 40462503 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  104. [104]

    Cseh A, Galimard JE, de la Fuente J et al.. “Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties.” British journal of haematology (2023). PMID: 37795523 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  105. [105]

    Brousse V, Kossorotoff M, de Montalembert M. “How I manage cerebral vasculopathy in children with sickle cell disease.” British journal of haematology (2015). PMID: 25944412 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  106. [106]

    Wilson SR, Noubouossie D, Little JA et al.. “Real-world assessment of acute red cell exchange for stroke in sickle cell disease.” British journal of haematology (2025). PMID: 40415245 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 7. Acute & Emergency Management, History and Evolution of Treatment
  107. [107]

    El-Amin N, Lauzon SD, Nietert PJ et al.. “Which adults with sickle cell disease need an evaluation for pulmonary embolism?” British journal of haematology (2021). PMID: 34472094 ↗

    L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  108. [108]

    Campbell AIK, Xu Y, Skeith L et al.. “Racial and ethnic disparities in eligibility for postpartum venous thromboembolism prophylaxis in the United States.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37838240 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 13. Special Populations & Pregnancy
  109. [109]

    Whelihan MF, Lim MY, Mooberry MJ et al.. “Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 27430959 ↗

    L3OTHERCited in: 3. Epidemiology, Etiology & Risk Factors
  110. [110]

    O'Toole G, Swan D, Connors JM et al.. “Hematological causes of acute ischemic stroke in younger individuals.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39393779 ↗

    L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  111. [111]

    Naik RP, Streiff MB, Haywood C et al.. “Venous thromboembolism incidence in the Cooperative Study of Sickle Cell Disease.” Journal of thrombosis and haemostasis : JTH (2014). PMID: 25280124 ↗

    L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Complications, 12. Prognosis & Natural History
  112. [112]

    Alvarez OA, Lerebours E, Paul Hanna M et al.. “Baseline Characteristics and Social Challenges of Children with Sickle Cell Disease in Haiti and after Immigration to the United States: A Comparative Cohort Study.” Journal of racial and ethnic health disparities (2026). PMID: 42323490 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors, 8. Long-term & Definitive Management
  113. [113]

    Hayford K, Tort MJ, Huang L et al.. “Clinical effectiveness and impact of 13-valent pneumococcal conjugate vaccines in preventing invasive pneumococcal disease among children with risk conditions: A systematic literature review.” Human vaccines & immunotherapeutics (2026). PMID: 41560367 ↗

    L2SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors
  114. [114]

    de Almeida Barros VM, Silva-Pinto AC, Moura PG et al.. “Risk of vaso-occlusive crisis requiring hospitalization in sickle cell disease patients in brazil: retrospective cohort study of real-world data.” Annals of hematology (2026). PMID: 41711948 ↗

    L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors, 7. Acute & Emergency Management
  115. [115]

    Gladwin MT, Gordeuk VR, Desai PC et al.. “Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial.” The Lancet. Haematology (2024). PMID: 38554715 ↗

    L1RCTCited in: 4. Clinical Presentation, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  116. [116]

    Mahlangu J, Colombatti R, James J et al.. “Motivators and barriers affecting decisions to participate in sickle cell disease clinical trials in the global Learning and Insights into Sickle Cell Trial Experiences (LISTEN) Survey: global and regional findings.” The Lancet. Haematology (2025). PMID: 41338865 ↗

    L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation
  117. [117]

    Jonassaint CR, Lalama CM, Carroll CP et al.. “Digital cognitive behavioral therapy vs education for pain in adults with sickle cell disease.” Blood advances (2024). PMID: 39374587 ↗

    L1RCTCited in: 4. Clinical Presentation, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  118. [118]

    Lee LH, Whisenton LH, Benger J et al.. “A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers.” Blood advances (2021). PMID: 34543385 ↗

    L4TRIAL_NONRANDOMCited in: 4. Clinical Presentation
  119. [119]

    Jonassaint CR, Jones VL, Leong S et al.. “A systematic review of the association between depression and health care utilization in children and adults with sickle cell disease.” British journal of haematology (2016). PMID: 26991317 ↗

    L2SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  120. [120]

    Oligbu G, Fallaha M, Pay L et al.. “Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature.” British journal of haematology (2019). PMID: 30859558 ↗

    L2SR_OBSCited in: 4. Clinical Presentation, 11. Complications
  121. [121]

    Rossi M, Pirenne F, Le Roux E et al.. “Delayed haemolytic transfusion reaction in paediatric patients with sickle cell disease: A retrospective study in a French national reference centre.” British journal of haematology (2022). PMID: 36541848 ↗

    L4COHORTCited in: 4. Clinical Presentation
  122. [122]

    Thein SL, Howard J. “How I treat the older adult with sickle cell disease.” Blood (2018). PMID: 30206116 ↗

    L5CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History
  123. [123]

    Pirenne F, Yazdanbakhsh K. “How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.” Blood (2018). PMID: 29724898 ↗

    L5CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  124. [124]

    Machogu EM, Machado RF. “How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders.” Blood (2018). PMID: 30206115 ↗

    L5CASE_REPORTCited in: 4. Clinical Presentation, History and Evolution of Treatment
  125. [125]

    Sharpe CC, Thein SL. “How I treat renal complications in sickle cell disease.” Blood (2014). PMID: 24764565 ↗

    L5CASE_REPORTCited in: 4. Clinical Presentation
  126. [126]

    Xi C, Pang J, Zhi W et al.. “Nrf2 sensitizes ferroptosis through l-2-hydroxyglutarate-mediated chromatin modifications in sickle cell disease.” Blood (2023). PMID: 37267508 ↗

    L5OTHERCited in: 4. Clinical Presentation
  127. [127]

    Miller ST. “How I treat acute chest syndrome in children with sickle cell disease.” Blood (2011). PMID: 21406723 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 11. Complications
  128. [128]

    Calis JC, Phiri KS, Faragher EB et al.. “Severe anemia in Malawian children.” The New England journal of medicine (2008). PMID: 18305266 ↗

    L3OTHERCited in: 4. Clinical Presentation, 11. Complications
  129. [129]

    Noizat-Pirenne F, Bachir D, Chadebech P et al.. “Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease.” Haematologica (2007). PMID: 18055978 ↗

    L4CASE_REPORTCited in: 4. Clinical Presentation, 11. Complications, 14. Prevention, Screening & Surveillance
  130. [130]

    Gardner K, Hoppe C, Mijovic A et al.. “How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.” British journal of haematology (2015). PMID: 25967919 ↗

    L5CASE_REPORTCited in: 4. Clinical Presentation
  131. [131]

    Gonzalez Sepulveda JM, Yang JC, Reed SD et al.. “Preferences for potential benefits and risks for gene therapy in the treatment of sickle cell disease.” Blood advances (2023). PMID: 37905989 ↗

    L2OTHERCited in: 4. Clinical Presentation
  132. [132]

    Agawu A, Nortey N, Jacobs C et al.. “Respiratory phenotype and health care utilization patterns by adults with sickle cell disease.” Blood advances (2025). PMID: 39368809 ↗

    L2OTHERCited in: 4. Clinical Presentation, 7. Acute & Emergency Management
  133. [133]

    Messimeris D, Bismuth H, Provost C et al.. “Determinants of cognitive dysfunction in adults with sickle cell-related stroke or suspected neurological morbidity.” Blood advances (2024). PMID: 38815229 ↗

    L4OTHERCited in: 4. Clinical Presentation
  134. [134]

    Ibanez V, Vaitkus K, Zhang X et al.. “Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF.” Blood advances (2023). PMID: 36884303 ↗

    L5OTHERCited in: 4. Clinical Presentation
  135. [135]

    Adam SS, Flahiff CM, Kamble S et al.. “Depression, quality of life, and medical resource utilization in sickle cell disease.” Blood advances (2017). PMID: 29296845 ↗

    L2OTHERCited in: 4. Clinical Presentation
  136. [136]

    Piel FB, Tewari S, Brousse V et al.. “Associations between environmental factors and hospital admissions for sickle cell disease.” Haematologica (2016). PMID: 27909222 ↗

    L2OTHERCited in: 4. Clinical Presentation
  137. [137]

    Tewari S, Brousse V, Piel FB et al.. “Environmental determinants of severity in sickle cell disease.” Haematologica (2015). PMID: 26341524 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 11. Complications
  138. [138]

    D'Alessandro A, Nouraie SM, Zhang Y et al.. “Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment.” Haematologica (2023). PMID: 37439373 ↗

    L2OTHERCited in: 4. Clinical Presentation, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  139. [139]

    Pellegrin S, Severn CE, Toye AM. “Towards manufactured red blood cells for the treatment of inherited anemia.” Haematologica (2021). PMID: 34042406 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  140. [140]

    de Montalembert M, Dumont MD, Heilbronner C et al.. “Delayed hemolytic transfusion reaction in children with sickle cell disease.” Haematologica (2011). PMID: 21330322 ↗

    L4OTHERCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  141. [141]

    Rivers A, Vaitkus K, Ibanez V et al.. “The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis).” Haematologica (2016). PMID: 26858356 ↗

    L5OTHERCited in: 4. Clinical Presentation
  142. [142]

    Trompeter S, Roberts I. “Haemoglobin F modulation in childhood sickle cell disease.” British journal of haematology (2008). PMID: 19036119 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 8. Long-term & Definitive Management, History and Evolution of Treatment
  143. [143]

    Rees DC, Robinson S, Howard J. “How I manage red cell transfusions in patients with sickle cell disease.” British journal of haematology (2018). PMID: 29377071 ↗

    L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  144. [144]

    van der Meer M, Velsink K, Tong WH et al.. “Is There a Difference in Occurrence of Complications Between Adults With Hemoglobin SS and Hemoglobin SC Disease: An Extended Systematic Review.” European journal of haematology (2026). PMID: 42297565 ↗

    L2SR_OBSCited in: 4. Clinical Presentation, 11. Complications, 14. Prevention, Screening & Surveillance
  145. [145]

    Paris J, Almater AI, Mackenzie C et al.. “Orbital involvement in sickle cell disease: A systematic review.” Survey of ophthalmology (2026). PMID: 42235647 ↗

    L4SR_OBSCited in: 4. Clinical Presentation, 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  146. [146]

    Molena KF, Costa MA, Paulo AC et al.. “High prevalence of molar-incisor hypomineralisation in sickle cell disease children and the association with haematologic profile: a retrospective cohort study.” European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry (2026). PMID: 42313255 ↗

    L2COHORTCited in: 4. Clinical Presentation
  147. [147]

    Rodgers-Melnick SN, Gunzler D, Love TE et al.. “Longitudinal effects of inpatient music therapy dosage on pain intensity and opioid utilization among patients with hematologic or oncologic conditions: a retrospective cohort study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42249214 ↗

    L2COHORTCited in: 4. Clinical Presentation, 8. Long-term & Definitive Management
  148. [148]

    Álvarez-Pérez Y, Duarte-Díaz A, Rivero-Santana A et al.. “Effectiveness of psychological interventions for children eligible for pediatric palliative care: systematic review and meta-analysis.” BMC pediatrics (2026). PMID: 41645150 ↗

    L1SR_OBSCited in: 4. Clinical Presentation
  149. [149]

    Idowu M, Otieno L, Dumitriu B et al.. “Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.” The Lancet. Haematology (2024). PMID: 39644907 ↗

    L1RCTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Prognosis & Natural History
  150. [150]

    Biemond BJ, Tombak A, Kilinc Y et al.. “Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet. Haematology (2021). PMID: 33894169 ↗

    L1RCTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications
  151. [151]

    Liem RI, Lanzkron S, D Coates T et al.. “American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.” Blood advances (2019). PMID: 31794601 ↗

    L1GUIDELINECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  152. [152]

    Kassim AA, de la Fuente J, Nur E et al.. “An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease.” Blood (2024). PMID: 38493482 ↗

    L4TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 12. Prognosis & Natural History
  153. [153]

    Bolaños-Meade J, Cooke KR, Gamper CJ et al.. “Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial.” The Lancet. Haematology (2019). PMID: 30878319 ↗

    L4TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  154. [154]

    Weeks LD, Wilson AM, Naik RP et al.. “Sickle cell trait does not cause "sickle cell crisis" leading to exertion-related death: a systematic review.” Blood (2025). PMID: 39882975 ↗

    L2SR_OBSCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 12. Prognosis & Natural History
  155. [155]

    Frangoul H, Altshuler D, Cappellini MD et al.. “CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.” The New England journal of medicine (2020). PMID: 33283989 ↗

    L4TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  156. [156]

    Eapen M, Brazauskas R, Walters MC et al.. “Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.” The Lancet. Haematology (2019). PMID: 31495699 ↗

    L3COHORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 12. Prognosis & Natural History
  157. [157]

    Sharma A, Locatelli F, Bhatia M et al.. “Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.” Blood advances (2025). PMID: 40857358 ↗

    L4TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 13. Special Populations & Pregnancy
  158. [158]

    Dhedin N, Bruno B, Paillard C et al.. “HLA-haploidentical hematopoietic stem cell transplantation in patients with sickle cell disease: results from the phase II DREP-HAPLO trial.” Haematologica (2025). PMID: 41376570 ↗

    L4TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  159. [159]

    Lagresle-Peyrou C, Lefrère F, Magrin E et al.. “Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.” Haematologica (2018). PMID: 29472357 ↗

    L4TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications
  160. [160]

    Goyal S, Tisdale J, Schmidt M et al.. “Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.” The New England journal of medicine (2021). PMID: 34898140 ↗

    L4CASE_REPORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management
  161. [161]

    Khandros E, Blobel GA. “Elevating fetal hemoglobin: recently discovered regulators and mechanisms.” Blood (2024). PMID: 38728575 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management
  162. [162]

    Gordeuk VR, Castro OL, Machado RF. “Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.” Blood (2016). PMID: 26758918 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  163. [163]

    Joseph L, Driessen M. “A comprehensive view of pregnancy in patients with sickle cell disease in high-income countries: the need for robust data and further decline in morbidity and mortality.” The Lancet. Haematology (2024). PMID: 38135375 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 11. Complications, 13. Special Populations & Pregnancy
  164. [164]

    Nnodu OE, Sopekan A, Nnebe-Agumadu U et al.. “Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study.” The Lancet. Haematology (2020). PMID: 32589979 ↗

    L4OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  165. [165]

    DeBaun MR, Jordan LC, King AA et al.. “American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.” Blood advances (2020). PMID: 32298430 ↗

    L1OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 14. Prevention, Screening & Surveillance
  166. [166]

    Grunenwald A, Peliconi J, Lavergne J et al.. “Transcriptomic atlas reveals organ-specific disease tolerance in sickle cell mice.” Blood advances (2025). PMID: 39841947 ↗

    L5OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  167. [167]

    Gendreau S, Coupry LM, Cappy P et al.. “Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units.” Blood advances (2025). PMID: 40526829 ↗

    L3OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 11. Complications
  168. [168]

    Selma J, Song H, Rivera C et al.. “Sickle cell disease promotes sex-dependent pathological bone loss through enhanced cathepsin proteolytic activity in mice.” Blood advances (2022). PMID: 34547771 ↗

    L5OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  169. [169]

    Olaniyan HS, Briscoe C, Muhongo M et al.. “Early diagnosis of sickle cell disease at birth hospitals and vaccination centers in Angola using point-of-care tests.” Blood advances (2023). PMID: 37399450 ↗

    L4OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  170. [170]

    El Hoss S, Cochet S, Godard A et al.. “Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease.” Haematologica (2021). PMID: 32855279 ↗

    L5OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  171. [171]

    Ataga KI, Moore CG, Hillery CA et al.. “Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.” Haematologica (2008). PMID: 18166781 ↗

    L4OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  172. [172]

    Lionnet F, Hammoudi N, Stojanovic KS et al.. “Hemoglobin sickle cell disease complications: a clinical study of 179 cases.” Haematologica (2012). PMID: 22315500 ↗

    L4OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  173. [173]

    Venugopal J, Wang J, Mawri J et al.. “Interleukin-1 receptor inhibition reduces stroke size in a murine model of sickle cell disease.” Haematologica (2021). PMID: 32817286 ↗

    L5OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  174. [174]

    McArthur JG, Svenstrup N, Chen C et al.. “A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease.” Haematologica (2019). PMID: 31147439 ↗

    L5OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  175. [175]

    Alkobtawi M, Sbeih M, Souaid K et al.. “Contribution of fetal microchimeric cells to maternal wound healing in sickle cell ulcers.” Haematologica (2023). PMID: 36373248 ↗

    L5OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 11. Complications, 13. Special Populations & Pregnancy
  176. [176]

    Hebbel RP, Key NS. “Microparticles in sickle cell anaemia: promise and pitfalls.” British journal of haematology (2016). PMID: 27136195 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  177. [177]

    Daniel Y, Henthorn J. “Lessons learnt in the screening and diagnosis of haemoglobinopathies.” British journal of haematology (2023). PMID: 37932940 ↗

    L4REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  178. [178]

    Pinto FO, Roberts I. “Cord blood stem cell transplantation for haemoglobinopathies.” British journal of haematology (2008). PMID: 18307566 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  179. [179]

    Early ML, Raja M, Luo A et al.. “Blood pressure thresholds for the diagnosis of hypertensive disorders of pregnancy in sickle cell disease.” British journal of haematology (2023). PMID: 38093478 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 13. Special Populations & Pregnancy
  180. [180]

    Chakravorty S, Dick MC. “Antenatal screening for haemoglobinopathies: current status, barriers and ethics.” British journal of haematology (2019). PMID: 31509241 ↗

    L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  181. [181]

    Ibemere SO, Oyedeji CI, Preiss L et al.. “Characterising the prevalence of overweight and obese status among adults with sickle cell disease.” British journal of haematology (2022). PMID: 36382420 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  182. [182]

    Setty BN, Betal SG, Zhang J et al.. “Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18983524 ↗

    L5OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  183. [183]

    Martens MJ, Lian Q, Logan BR. “TITE-safety: a robust time-to-event safety monitoring approach for clinical trials.” Biometrics (2026). PMID: 42201841 ↗

    L5TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 8. Long-term & Definitive Management, 11. Complications
  184. [184]

    Alasbali R, Alzahrani M, Wilkerson K et al.. “Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease.” Bone marrow transplantation (2026). PMID: 42049986 ↗

    L4TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications, 12. Prognosis & Natural History
  185. [185]

    Yee MEM, Zerra PE, Francis RO et al.. “Red blood cell transfusion survival in sickle cell disease is reduced by donor characteristics and recipient spleen activity.” Blood advances (2026). PMID: 42018645 ↗

    L2TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  186. [186]

    Das S, Ghai G, Sathianath S et al.. “Systematic Review and Meta-analysis on the Prevalence of Common Hemoglobinopathies in India.” Annals of African medicine (2026). PMID: 41943545 ↗

    L1SR_OBSCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 14. Prevention, Screening & Surveillance
  187. [187]

    Adelabu Y, Fakile UO, Oladimeji WQ et al.. “Bladder mass following bone marrow transplant for sickle cell disease: A diagnostic dilemma.” Clinical hematology international (2026). PMID: 42099830 ↗

    L4CASE_REPORTCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  188. [188]

    Lembeck AL, Wölfler A, Zebisch A et al.. “Fish-shaped erythrocytes and pincer cells co-occur in distinct hematological disorders and are associated with anemia severity.” Clinical chemistry and laboratory medicine (2026). PMID: 42406051 ↗

    L4OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  189. [189]

    Wasilwa MO, Simiyu V, Onduru F et al.. “Infectious pathogens associated with stillbirth and under-five mortality by sickle cell disease in Western Kenya: a cross-sectional study.” BMC infectious diseases (2026). PMID: 42380786 ↗

    L2OTHERCited in: 5. Diagnosis & Workup: Smear, Marrow, Flow Cytometry & Molecular Profiling
  190. [190]

    Farrell AT, Panepinto J, Carroll CP et al.. “End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.” Blood advances (2019). PMID: 31809538 ↗

    L1TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  191. [191]

    Al Balushi HWM, Wali Y, Al Awadi M et al.. “The super sickling haemoglobin HbS-Oman: a study of red cell sickling, K+ permeability and associations with disease severity in patients heterozygous for HbA and HbS-Oman (HbA/S-Oman genotype).” British journal of haematology (2017). PMID: 28699687 ↗

    L3TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  192. [192]

    Kim MG, Yu K, Yeh CY et al.. “Low-intensity transcranial focused ultrasound suppresses pain by modulating pain-processing brain circuits.” Blood (2024). PMID: 38976875 ↗

    L5OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management
  193. [193]

    Brazauskas R, Scigliuolo GM, Wang HL et al.. “Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease.” Blood (2020). PMID: 32518950 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  194. [194]

    Chen Q, Hazra R, Crosby D et al.. “Heme-induced loss of renovascular endothelial protein C receptor promotes chronic kidney disease in sickle mice.” Blood (2024). PMID: 38820589 ↗

    L5OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  195. [195]

    Escobar Alvarez SN, Myers ER. “Impact of a grant program to spur advances in sickle cell disease research.” Blood advances (2021). PMID: 34570224 ↗

    L5OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  196. [196]

    Chang TC, Yu J, Wang Z et al.. “Machine learning to optimize automated RH genotyping using whole-exome sequencing data.” Blood advances (2024). PMID: 38522094 ↗

    L4OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  197. [197]

    McCuskee S, Liu Z, Lee HC et al.. “Retinal imaging and supervised learning predict hospitalizations and kidney and heart-lung damage in sickle cell disease.” Blood advances (2026). PMID: 42059643 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  198. [198]

    Chang TC, Haupfear KM, Yu J et al.. “A novel algorithm comprehensively characterizes human RH genes using whole-genome sequencing data.” Blood advances (2020). PMID: 32915977 ↗

    L4OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  199. [199]

    Ladisa F, Morelli E, Soncini D et al.. “CRISPR application in hematological disorders: from bench to bedside.” Blood advances (2026). PMID: 42263664 ↗

    L5OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  200. [200]

    Allali S, Taylor M, Brice J et al.. “Chronic organ injuries in children with sickle cell disease.” Haematologica (2021). PMID: 33626864 ↗

    L5OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, 14. Prevention, Screening & Surveillance
  201. [201]

    Ray R, Li H, Gao S et al.. “Variations in mitochondrial genome as potential prognostic markers in sickle cell disease.” Haematologica (2026). PMID: 41852318 ↗

    L4OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  202. [202]

    Voskaridou E, Tsetsos G, Tsoutsias A et al.. “Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.” Haematologica (2007). PMID: 17550845 ↗

    L4OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  203. [203]

    Ataga KI, Stocker J. “The trials and hopes for drug development in sickle cell disease.” British journal of haematology (2015). PMID: 26123612 ↗

    L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  204. [204]

    Brewin J, Kaya B, Chakravorty S. “How I manage sickle cell patients with high transcranial doppler results.” British journal of haematology (2017). PMID: 28771666 ↗

    L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring
  205. [205]

    Sachdev V, Tian X, Gu Y et al.. “A phenotypic risk score for predicting mortality in sickle cell disease.” British journal of haematology (2021). PMID: 33506990 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  206. [206]

    Václavů L, Baldew ZAV, Gevers S et al.. “Intracranial 4D flow magnetic resonance imaging reveals altered haemodynamics in sickle cell disease.” British journal of haematology (2017). PMID: 29270975 ↗

    L3OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  207. [207]

    Dexter D, McGann PT. “Saving lives through early diagnosis: the promise and role of point of care testing for sickle cell disease.” British journal of haematology (2021). PMID: 34340260 ↗

    L5OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  208. [208]

    Hines PC, Callaghan MU, Zaidi AU et al.. “Flow adhesion of whole blood to P-selectin: a prognostic biomarker for vaso-occlusive crisis in sickle cell disease.” British journal of haematology (2021). PMID: 34472086 ↗

    L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  209. [209]

    Ali NT, Abdullah RS, Mehdi MAH et al.. “AI-Augmented Hematological Signatures for Equitable Detection of Hereditary Hemolytic Anemia Carriers: A Global Systematic Review and Meta-Analysis.” Human mutation (2026). PMID: 42369207 ↗

    L1SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 14. Prevention, Screening & Surveillance
  210. [210]

    Bills SE, Schatz J, Gillooly E et al.. “Academic and cerebrovascular outcomes after neurodevelopmental screening in sickle cell disease: A longitudinal cohort study.” Developmental medicine and child neurology (2025). PMID: 41235698 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  211. [211]

    Alamin AA, Yahia AIO, Ibrahim E et al.. “Platelet-Red Blood Cell Interactions in Thrombosis: Integrating Hemodynamic, Molecular, and Clinical Evidence-A Systematic Review.” Seminars in thrombosis and hemostasis (2026). PMID: 42190738 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  212. [212]

    Almarshad HA. “Blood viscosity in clinical practice: A critical review of diagnostic utility, therapeutic implications, and evidence gaps.” Clinical hemorheology and microcirculation (2026). PMID: 42089664 ↗

    L5SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  213. [213]

    Resta C, Xiong R, Sturrock S et al.. “Non-invasive prenatal testing for the diagnosis of sickle cell disease in high-risk pregnancies: A systematic review and statistical summary of the current literature.” European journal of obstetrics, gynecology, and reproductive biology (2025). PMID: 41192133 ↗

    L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  214. [214]

    Alwaheed AJ, Alqatari SG, Alalwan SJ et al.. “The Role of Platelet-to-Neutrophil Ratio as a Biomarker for Pulmonary Hypertension in Sickle Cell Disease Patients: A Retrospective Cohort Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42075644 ↗

    L3COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  215. [215]

    Belisário AR, Ozahata MC, Moura ICG et al.. “Laboratory and genetic characteristic associated with gallbladder-related outcomes in sickle cell disease in Brazil: results from the REDS-III multicenter cohort study.” Annals of hematology (2026). PMID: 41692868 ↗

    L2COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring
  216. [216]

    Morris CR, Brown LAS, Reynolds M et al.. “Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain.” Blood (2020). PMID: 32384147 ↗

    L1RCTCited in: 7. Acute & Emergency Management
  217. [217]

    Bain BJ, Daniel Y, Henthorn J et al.. “Significant haemoglobinopathies: A guideline for screening and diagnosis: A British Society for Haematology Guideline: A British Society for Haematology Guideline.” British journal of haematology (2023). PMID: 37271570 ↗

    L1GUIDELINECited in: 7. Acute & Emergency Management
  218. [218]

    Morris CR, Kuypers FA, Lavrisha L et al.. “A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes.” Haematologica (2013). PMID: 23645695 ↗

    L1RCTCited in: 7. Acute & Emergency Management, History and Evolution of Treatment
  219. [219]

    Siewny L, King A, Melvin CL et al.. “Impact of an individualized pain plan to treat sickle cell disease vaso-occlusive episodes in the emergency department.” Blood advances (2024). PMID: 38815230 ↗

    L2TRIAL_NONRANDOMCited in: 7. Acute & Emergency Management
  220. [220]

    Lobo CL, Pinto JF, Nascimento EM et al.. “The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.” British journal of haematology (2013). PMID: 23590693 ↗

    L3TRIAL_NONRANDOMCited in: 7. Acute & Emergency Management
  221. [221]

    Karkoska K, Appiah-Kubi A, Rocker J et al.. “Management of vaso-occlusive episodes in the day hospital decreases admissions in children with sickle cell disease.” British journal of haematology (2019). PMID: 31148158 ↗

    L3TRIAL_NONRANDOMCited in: 7. Acute & Emergency Management
  222. [222]

    Rech JS, Cohen A, Bartolucci P et al.. “Shift in emergency department utilization by frequent attendees with sickle cell disease during the COVID-19 pandemic: A multicentre cohort study.” British journal of haematology (2024). PMID: 38960400 ↗

    L2COHORTCited in: 7. Acute & Emergency Management
  223. [223]

    Zhou J, Han J, Nutescu EA et al.. “Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study.” British journal of haematology (2018). PMID: 29767446 ↗

    L3COHORTCited in: 7. Acute & Emergency Management
  224. [224]

    Ballas SK, Gupta K, Adams-Graves P. “Sickle cell pain: a critical reappraisal.” Blood (2012). PMID: 22923496 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute & Emergency Management
  225. [225]

    Hillery CA, Kerstein PC, Vilceanu D et al.. “Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease.” Blood (2011). PMID: 21708890 ↗

    L5OTHERCited in: 7. Acute & Emergency Management
  226. [226]

    Hariharan N, Brunson A, Mahajan A et al.. “Bleeding in patients with sickle cell disease: a population-based study.” Blood advances (2020). PMID: 32108229 ↗

    L2OTHERCited in: 7. Acute & Emergency Management
  227. [227]

    Howell KE, Kayle M, Smeltzer MP et al.. “Gaps during pediatric to adult care transfer escalate acute resource utilization in sickle cell disease.” Blood advances (2024). PMID: 38809136 ↗

    L2OTHERCited in: 7. Acute & Emergency Management
  228. [228]

    Wesevich A, Woelkers M, Adegunsoye A et al.. “Triaging acute chest syndrome clinical decision-making using bedside SaO2/FiO2 ratio.” Blood advances (2025). PMID: 40179390 ↗

    L2OTHERCited in: 7. Acute & Emergency Management
  229. [229]

    MacEwan SR, Chiang C, O'Brien SH et al.. “Comparing super-utilizers and lower-utilizers among commercial- and Medicare-insured adults with sickle cell disease.” Blood advances (2024). PMID: 37991988 ↗

    L2OTHERCited in: 7. Acute & Emergency Management
  230. [230]

    Khan H, Kang G, Porter JS et al.. “Social determinants of health affect disease severity among preschool children with sickle cell disease.” Blood advances (2024). PMID: 39373640 ↗

    L2OTHERCited in: 7. Acute & Emergency Management
  231. [231]

    Coisy F, Simon A, Occelli C et al.. “Does a history of sickle cell disease affect the prescription of morphine? An international, randomised study based on clinical vignettes conducted among emergency physicians.” BMJ open (2025). PMID: 41448706 ↗

    L2RCTCited in: 7. Acute & Emergency Management
  232. [232]

    Adewoye AH, Nolan V, McMahon L et al.. “Effectiveness of a dedicated day hospital for management of acute sickle cell pain.” Haematologica (2007). PMID: 17550862 ↗

    L4OTHERCited in: 7. Acute & Emergency Management
  233. [233]

    Telfer P, Bahal N, Lo A et al.. “Management of the acute painful crisis in sickle cell disease- a re-evaluation of the use of opioids in adult patients.” British journal of haematology (2014). PMID: 24750050 ↗

    L5REVIEW_NARRATIVECited in: 7. Acute & Emergency Management
  234. [234]

    Khalid A, Riaño AS, Mohnkern JD et al.. “Early vs delayed opioid administration for pediatric sickle cell vaso-occlusive crisis: A systematic review and meta-analysis.” The American journal of emergency medicine (2026). PMID: 42190636 ↗

    L1SR_OBSCited in: 7. Acute & Emergency Management, 13. Special Populations & Pregnancy
  235. [235]

    Amenah DB, Afaya A, Klinogo F et al.. “Sociocultural and health system determinants of maternal mortality in Ghana: findings from a systematic review.” BMC public health (2026). PMID: 41794701 ↗

    L1SR_OBSCited in: 7. Acute & Emergency Management
  236. [236]

    Rice CT, Besser M, Baker CL et al.. “Empirical estimate for the indirect healthcare costs of sickle cell disease from a retrospective cohort study in England between 2007 and 2019.” BMC health services research (2026). PMID: 42243888 ↗

    L2COHORTCited in: 7. Acute & Emergency Management
  237. [237]

    Owusu-Antwi P, Muhialdain M, Atodaria P et al.. “Risperidone-Induced Priapism: A Systematic Review of Risk Factors, Comprehensive Assessment, and Management Recommendations.” Journal of clinical psychopharmacology (2026). PMID: 41930469 ↗

    L1SR_OBSCited in: 7. Acute & Emergency Management
  238. [238]

    Belton TD, Steinway CM, Teng O et al.. “The Community Health Workers and Mobile Health for Emerging Adults Transitioning Sickle Cell Disease Care (COMETS) Trial: Protocol for a Randomized Controlled Trial.” JMIR research protocols (2025). PMID: 40905609 ↗

    L5TRIAL_NONRANDOMCited in: 7. Acute & Emergency Management
  239. [239]

    Chou ST, Alsawas M, Fasano RM et al.. “American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.” Blood advances (2020). PMID: 31985807 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  240. [240]

    Kanter J, Liem RI, Bernaudin F et al.. “American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation.” Blood advances (2021). PMID: 34581773 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, History and Evolution of Treatment
  241. [241]

    Angelucci E, Matthes-Martin S, Baronciani D et al.. “Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.” Haematologica (2014). PMID: 24790059 ↗

    L1GUIDELINECited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  242. [242]

    Saraf SL, Hagar R, Idowu M et al.. “Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.” Blood advances (2024). PMID: 38640200 ↗

    L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment
  243. [243]

    Frangoul H, Locatelli F, Sharma A et al.. “Exagamglogene Autotemcel for Severe Sickle Cell Disease.” The New England journal of medicine (2024). PMID: 38661449 ↗

    L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 14. Prevention, Screening & Surveillance
  244. [244]

    Kanter J, Walters MC, Krishnamurti L et al.. “Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.” The New England journal of medicine (2021). PMID: 34898139 ↗

    L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment
  245. [245]

    Esrick EB, Lehmann LE, Biffi A et al.. “Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.” The New England journal of medicine (2020). PMID: 33283990 ↗

    L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management
  246. [246]

    Gupta AO, Sharma A, Frangoul H et al.. “Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.” The New England journal of medicine (2026). PMID: 41931046 ↗

    L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  247. [247]

    Hanna R, Frangoul H, Pineiro L et al.. “CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.” The New England journal of medicine (2026). PMID: 41931047 ↗

    L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  248. [248]

    Hsieh MM, Kang EM, Fitzhugh CD et al.. “Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.” The New England journal of medicine (2009). PMID: 20007560 ↗

    L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy
  249. [249]

    van Dijk MJ, Rab MAE, van Oirschot BA et al.. “One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.” Blood advances (2023). PMID: 37934880 ↗

    L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 11. Complications
  250. [250]

    Le K, Wang X, Chu J et al.. “Activating pyruvate kinase improves red blood cell integrity by reducing band 3 tyrosine phosphorylation.” Blood advances (2024). PMID: 39265169 ↗

    L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 12. Prognosis & Natural History
  251. [251]

    D'Alessandro A, Le K, Lundt M et al.. “Functional and multi-omics signatures of mitapivat efficacy upon activation of pyruvate kinase in red blood cells from patients with sickle cell disease.” Haematologica (2024). PMID: 38450513 ↗

    L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management
  252. [252]

    Lopinto J, Gendreau S, Berti E et al.. “Effects of corticosteroids in patients with sickle cell disease and acute complications: a systematic review and meta-analysis.” Haematologica (2022). PMID: 35021607 ↗

    L1SR_OBSCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  253. [253]

    Sharma A. “How I treat sickle cell disease with gene therapy.” Blood (2024). PMID: 39356871 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Complications, 14. Prevention, Screening & Surveillance
  254. [254]

    Gallagher PG. “Disorders of erythrocyte hydration.” Blood (2017). PMID: 29051181 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 14. Prevention, Screening & Surveillance
  255. [255]

    Wang Y, Yu L, Deng K et al.. “Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model.” Blood (2025). PMID: 40332031 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management
  256. [256]

    Vats R, Kaminski TW, Brzoska T et al.. “Liver-to-lung microembolic NETs promote gasdermin D-dependent inflammatory lung injury in sickle cell disease.” Blood (2022). PMID: 35737916 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  257. [257]

    Nguyen KA, Matte A, Foresti R et al.. “An oral carbon monoxide-releasing molecule protects against acute hyperhemolysis in sickle cell disease.” Blood (2024). PMID: 38518106 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 11. Complications
  258. [258]

    Drown L, Osei M, Thapa A et al.. “Models of care for sickle cell disease in low-income and lower-middle-income countries: a scoping review.” The Lancet. Haematology (2024). PMID: 38432241 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  259. [259]

    Pecker LH, Oteng-Ntim E, Nero A et al.. “Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care.” The Lancet. Haematology (2023). PMID: 36708736 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 13. Special Populations & Pregnancy, 14. Prevention, Screening & Surveillance
  260. [260]

    Pirenne F, Floch A, Diop S. “Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries.” The Lancet. Haematology (2023). PMID: 37060916 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  261. [261]

    de la Fuente J, Gluckman E, Makani J et al.. “The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing.” The Lancet. Haematology (2020). PMID: 33242447 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  262. [262]

    Frangoul H, de la Fuente J, Chopra Y et al.. “Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease.” The New England journal of medicine (2026). PMID: 42274009 ↗

    L4OTHERCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  263. [263]

    Brandow AM, Carroll CP, Creary S et al.. “American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.” Blood advances (2020). PMID: 32559294 ↗

    L1OTHERCited in: 8. Long-term & Definitive Management
  264. [264]

    Lanzkron S, Manwani D, Desai P et al.. “GRNDaD: big data and sickle cell disease.” Blood advances (2022). PMID: 35133406 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment
  265. [265]

    Taher AT, Weatherall DJ, Cappellini MD. “Thalassaemia.” Lancet (London, England) (2017). PMID: 28774421 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  266. [266]

    Higgs DR, Engel JD, Stamatoyannopoulos G. “Thalassaemia.” Lancet (London, England) (2011). PMID: 21908035 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  267. [267]

    Doeven T, Glenthøj A, Grace RF et al.. “Pyruvate kinase activators in hereditary haemolytic anaemias: current evidence and clinical potential.” Lancet (London, England) (2026). PMID: 41833294 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  268. [268]

    Oakley LL, McDermott C, Robinson V et al.. “The acceptability and feasibility of a randomised controlled trial of serial prophylactic exchange blood transfusion versus usual care in pregnant women with sickle cell disease: a qualitative study.” BMC pregnancy and childbirth (2026). PMID: 42399799 ↗

    L5RCTCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  269. [269]

    Linder GE, Chou ST. “Red cell transfusion and alloimmunization in sickle cell disease.” Haematologica (2021). PMID: 33792218 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  270. [270]

    Geisness AC, Azul M, Williams D et al.. “Ionophore-mediated swelling of erythrocytes as a therapeutic mechanism in sickle cell disease.” Haematologica (2022). PMID: 34706495 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, 11. Complications, 14. Prevention, Screening & Surveillance
  271. [271]

    Saraf SL, Zhang X, Shah B et al.. “Genetic variants and cell-free hemoglobin processing in sickle cell nephropathy.” Haematologica (2015). PMID: 26206798 ↗

    L2OTHERCited in: 8. Long-term & Definitive Management
  272. [272]

    Khasabova IA, Gable J, Johns M et al.. “Inhibition of DAGLβ as a therapeutic target for pain in sickle cell disease.” Haematologica (2023). PMID: 35615929 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management
  273. [273]

    Rossato P, Federti E, Matte A et al.. “Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease.” Haematologica (2022). PMID: 35443560 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management
  274. [274]

    Nardo-Marino A, Brousse V, Rees D. “Emerging therapies in sickle cell disease.” British journal of haematology (2020). PMID: 32142156 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  275. [275]

    Sobota A, Sabharwal V, Fonebi G et al.. “How we prevent and manage infection in sickle cell disease.” British journal of haematology (2015). PMID: 26018640 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 11. Complications, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  276. [276]

    Lucania G, Vitrano A, Filosa A et al.. “Chelation treatment in sickle-cell-anaemia: much ado about nothing?” British journal of haematology (2011). PMID: 21707578 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  277. [277]

    Shandley LM, Fasano RM, Spencer JB et al.. “The impact of sickle cell disease and its treatment on ovarian reserve in reproductive-aged Black women.” British journal of haematology (2024). PMID: 38841818 ↗

    L4OTHERCited in: 8. Long-term & Definitive Management
  278. [278]

    Mishkin AD, Prince EJ, Leimbach EJ et al.. “Psychiatric comorbidities in adults with sickle cell disease: A narrative review.” British journal of haematology (2023). PMID: 37455514 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management
  279. [279]

    Voskaridou E, Christoulas D, Terpos E. “Sickle-cell disease and the heart: review of the current literature.” British journal of haematology (2012). PMID: 22530942 ↗

    L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  280. [280]

    Segbefia C, Luchtman-Jones L. “Seeing haemoglobin SC: Challenging the misperceptions.” British journal of haematology (2024). PMID: 38922871 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management
  281. [281]

    Hunt RC, Katneni U, Yalamanoglu A et al.. “Contribution of ADAMTS13-independent VWF regulation in sickle cell disease.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35753044 ↗

    L4OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  282. [282]

    Stivala S, Gobbato S, Bonetti N et al.. “Dietary alpha-linolenic acid reduces platelet activation and collagen-mediated cell adhesion in sickle cell disease mice.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34758193 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  283. [283]

    Rossato P, Glantschnig H, Canneva F et al.. “Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36700507 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management
  284. [284]

    Annarapu GK, Nolfi-Donegan D, Reynolds M et al.. “Mitochondrial reactive oxygen species scavenging attenuates thrombus formation in a murine model of sickle cell disease.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33724688 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  285. [285]

    Wang J, Silaghi P, Eitzman DT. “Sickle hemoglobin promotes venous thrombosis through procoagulant activity and is targetable by hemoglobinase therapy.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41941897 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management
  286. [286]

    Shaik MY, Divers S. “Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials.” European journal of haematology (2026). PMID: 42400217 ↗

    L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  287. [287]

    Andemariam B, Wufsus A, Hecht E et al.. “Motivators and Barriers Affecting Decisions to Participate in Clinical Trials for Sickle Cell Disease: United States Findings from the Quantitative LISTEN Survey.” Journal of racial and ethnic health disparities (2026). PMID: 42323491 ↗

    L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management
  288. [288]

    Zimmerman EI, Callegari E, Sharma R et al.. “A Phase 1 Microtracer Study Evaluating the Mass Balance, Excretion, and Pharmacokinetics of Osivelotor in Healthy Participants.” Clinical and translational science (2026). PMID: 42183775 ↗

    L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management
  289. [289]

    Zhou X, Ma T, Ding X et al.. “The evolving landscape of gene editing therapies for human genetic diseases: a twenty-year bibliometric analysis.” Frontiers in medicine (2026). PMID: 42318429 ↗

    L5SR_OBSCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment
  290. [290]

    Alsalman M, Alnajjar JS, Alhassan SR et al.. “Global Prevalence of Alloimmunization in Adults with Sickle Cell Disease Receiving Red Blood Cell Transfusions: A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2026). PMID: 42194795 ↗

    L2SR_OBSCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  291. [291]

    Sharma A, Corbacioglu S. “Alternative Conditioning Regimens for Hemoglobinopathy Gene Therapy: Balancing Efficacy, Toxicity, and the Next Frontier.” Blood advances (2026). PMID: 42418372 ↗

    L5OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  292. [292]

    van der Veen S, Biemond BJ, Cnossen MH et al.. “Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.” American journal of hematology (2026). PMID: 42400197 ↗

    L4OTHERCited in: 8. Long-term & Definitive Management, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  293. [293]

    Bolaños-Meade J, Fuchs EJ, Luznik L et al.. “HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease.” Blood (2012). PMID: 22955919 ↗

    L4TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  294. [294]

    Sharma A, Boelens JJ, Cancio M et al.. “CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease.” The New England journal of medicine (2023). PMID: 37646679 ↗

    L4TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  295. [295]

    Nickel RS, Abraham A, Chiang KY et al.. “Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study.” Blood advances (2026). PMID: 41945757 ↗

    L4TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications
  296. [296]

    Alzahrani M, Damlaj M, Jeffries N et al.. “Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: outcomes from three independent centres.” British journal of haematology (2021). PMID: 33534948 ↗

    L4TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  297. [297]

    Nickel RS, Horan JT, Abraham A et al.. “Human leukocyte antigen (HLA) class I antibodies and transfusion support in paediatric HLA-matched haematopoietic cell transplant for sickle cell disease.” British journal of haematology (2019). PMID: 31674662 ↗

    L2TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  298. [298]

    Kassim AA, Galadanci NA, Pruthi S et al.. “How I treat and manage strokes in sickle cell disease.” Blood (2015). PMID: 25824688 ↗

    L5CASE_REPORTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 14. Prevention, Screening & Surveillance
  299. [299]

    Magrin E, Miccio A, Cavazzana M. “Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.” Blood (2019). PMID: 31467062 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  300. [300]

    Abraham AA, Tisdale JF. “Gene therapy for sickle cell disease: moving from the bench to the bedside.” Blood (2021). PMID: 34232993 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 14. Prevention, Screening & Surveillance
  301. [301]

    Hsieh MM, Fitzhugh CD, Tisdale JF. “Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.” Blood (2011). PMID: 21628400 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications
  302. [302]

    Gluckman E, Cappelli B, Bernaudin F et al.. “Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.” Blood (2016). PMID: 27965196 ↗

    L2OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  303. [303]

    Arumugam PI, Mullins ES, Shanmukhappa SK et al.. “Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice.” Blood (2015). PMID: 26286849 ↗

    L5OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  304. [304]

    Jones RJ, DeBaun MR. “Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.” Blood (2021). PMID: 34115136 ↗

    L5OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  305. [305]

    Bernaudin F, Socie G, Kuentz M et al.. “Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease.” Blood (2007). PMID: 17606762 ↗

    L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  306. [306]

    Sharma A, Kassim A, Thompson A et al.. “Gene Therapy for Sickle Cell Disease: Practice Recommendations from the American Society for Transplantation and Cellular Therapy and the International Society for Cell & Gene Therapy.” Transplantation and cellular therapy (2026). PMID: 41905703 ↗

    L1GUIDELINECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, History and Evolution of Treatment
  307. [307]

    Hosoya H, Levine J, Abt P et al.. “Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.” Blood advances (2018). PMID: 29535106 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications
  308. [308]

    Kinoshita H, Mandava M, Jensen-Wachspress M et al.. “Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.” Blood advances (2023). PMID: 36516084 ↗

    L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 11. Complications
  309. [309]

    Leonard A, Furstenau D, Abraham A et al.. “Reduction in vaso-occlusive events following stem cell transplantation in patients with sickle cell disease.” Blood advances (2023). PMID: 36240296 ↗

    L2OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  310. [310]

    Shenoy S, Kanter J, Kassim A et al.. “A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease.” Blood advances (2025). PMID: 39993235 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  311. [311]

    Jones RJ, Kassim AA, Brodsky RA et al.. “Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?” Blood advances (2025). PMID: 39602668 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  312. [312]

    Tanhehco YC, Thibodeaux S, Shi PA et al.. “Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease.” Blood advances (2025). PMID: 41396678 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  313. [313]

    Magnani A, Pondarré C, Bouazza N et al.. “Extensive multilineage analysis in patients with mixed chimerism after allogeneic transplantation for sickle cell disease: insight into hematopoiesis and engraftment thresholds for gene therapy.” Haematologica (2019). PMID: 31537695 ↗

    L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  314. [314]

    Arnold SD, Brazauskas R, He N et al.. “Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.” Haematologica (2017). PMID: 28818869 ↗

    L2OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  315. [315]

    Andreani M, Testi M, Gaziev J et al.. “Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease.” Haematologica (2010). PMID: 20935000 ↗

    L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  316. [316]

    Kharya G, Nirmal G, Chadha V et al.. “Shifting paradigms from myeloablation to immune modulation: pre-transplant immune-suppression and post-transplant cyclophosphamide in human leucocyte antigen identical related donor hematopoietic stem cell transplantation for sickle cell disease.” Haematologica (2026). PMID: 42131937 ↗

    L5OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  317. [317]

    Arnold SD, Bhatia M, Horan J et al.. “Haematopoietic stem cell transplantation for sickle cell disease - current practice and new approaches.” British journal of haematology (2016). PMID: 27255787 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  318. [318]

    Leonard A, Tisdale J, Abraham A. “Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?” British journal of haematology (2020). PMID: 32034776 ↗

    L5REVIEW_NARRATIVECited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  319. [319]

    Peters C. “Haematopoietic stem cell transplantation in children with sickle cell disease: Still to do?” British journal of haematology (2023). PMID: 37957026 ↗

    L5OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  320. [320]

    Strocchio L, Zecca M, Comoli P et al.. “Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.” British journal of haematology (2015). PMID: 25818248 ↗

    L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  321. [321]

    Dedeken L, Lê PQ, Azzi N et al.. “Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients.” British journal of haematology (2014). PMID: 24433465 ↗

    L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  322. [322]

    Felfly H, Trudel M. “Successful correction of murine sickle cell disease with reduced stem cell requirements reinforced by fractionated marrow infusions.” British journal of haematology (2009). PMID: 19930185 ↗

    L5OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  323. [323]

    Panepinto JA, Walters MC, Carreras J et al.. “Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research.” British journal of haematology (2007). PMID: 17459050 ↗

    L4OTHERCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  324. [324]

    Folarin M, Al-Zubaidi H, Moore E et al.. “Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation in Curing Sickle Cell Disease: A Systematic Review and Meta-Analysis of Single-Arm Studies.” Transplantation and cellular therapy (2025). PMID: 40953733 ↗

    L1SR_OBSCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  325. [325]

    Javed D, Rai AK, Bansal S et al.. “Efficacy of Ayurveda Regimen as an Adjunct to Hydroxyurea in Sickle Cell Disease: Protocol for a Prospective, Randomized, Open-Label, Blinded End Point Exploratory Study.” JMIR research protocols (2026). PMID: 42054235 ↗

    L5TRIAL_NONRANDOMCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy, History and Evolution of Treatment
  326. [326]

    Colombatti R, Reggiani G. “Optimizing the "right" patient selection for treatment for sickle cell disease.” Hematology. American Society of Hematology. Education Program (2025). PMID: 41348018 ↗

    L5CASE_REPORTCited in: 9. Hematopoietic Cell Transplantation & Cellular Therapy
  327. [327]

    Maggio A, Kattamis A, Felisi M et al.. “Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.” The Lancet. Haematology (2020). PMID: 32470438 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment
  328. [328]

    Murad MH, Liem RI, Lang ES et al.. “2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations.” Blood advances (2019). PMID: 31794603 ↗

    L1GUIDELINECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  329. [329]

    Lizarralde-Iragorri MA, Parachalil Gopalan B, Merriweather B et al.. “Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial.” Blood advances (2024). PMID: 38157227 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  330. [330]

    Wolf J, Blais-Normandin I, Bathla A et al.. “Red cell specifications for blood group matching in patients with haemoglobinopathies: An updated systematic review and clinical practice guideline from the International Collaboration for Transfusion Medicine Guidelines.” British journal of haematology (2024). PMID: 39535318 ↗

    L2GUIDELINECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  331. [331]

    Howard J, Malfroy M, Llewelyn C et al.. “The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial.” Lancet (London, England) (2013). PMID: 23352054 ↗

    L1RCTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 11. Complications, 12. Prognosis & Natural History
  332. [332]

    Chou ST, Hendrickson JE. “How I treat challenging transfusion cases in sickle cell disease.” Blood (2025). PMID: 38728382 ↗

    L5CASE_REPORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History
  333. [333]

    Verduzco LA, Nathan DG. “Sickle cell disease and stroke.” Blood (2009). PMID: 19797523 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  334. [334]

    DeBaun MR, Kirkham FJ. “Central nervous system complications and management in sickle cell disease.” Blood (2016). PMID: 26758917 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  335. [335]

    Kato GJ. “Sickle cells and sickle trait in thrombosis.” Blood (2019). PMID: 31171540 ↗

    L5OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  336. [336]

    Bannow BS, Akpan I, Baldwin MK. “Female reproductive health-what the classical haematologist needs to know.” The Lancet. Haematology (2026). PMID: 42302802 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 13. Special Populations & Pregnancy
  337. [337]

    Zheng Y, Gossett JM, Chen PL et al.. “Proinflammatory state promotes red blood cell alloimmunization in pediatric patients with sickle cell disease.” Blood advances (2023). PMID: 37023228 ↗

    L3OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  338. [338]

    Fogarty H, Ahmad A, Atiq F et al.. “VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.” Blood advances (2023). PMID: 37773926 ↗

    L3OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  339. [339]

    Yaseen A, Suleiman S, Zenah OA et al.. “Red blood-cell alloantibodies in multiply transfused patients in the occupied Palestinian territory: a pilot study.” Lancet (London, England) (2018). PMID: 29553439 ↗

    L4OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  340. [340]

    Gotardo ÉMF, Torres LS, Zaidan BC et al.. “Targeting P-selectin and interleukin-1β in mice with sickle cell disease: effects on vaso-occlusion, liver injury and organ iron deposition.” Haematologica (2025). PMID: 39568425 ↗

    L5OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  341. [341]

    Mattè A, Federti E, Recchiuti A et al.. “Epeleuton, a novel synthetic ω-3 fatty acid, reduces hypoxia/ reperfusion stress in a mouse model of sickle cell disease.” Haematologica (2024). PMID: 38105727 ↗

    L5OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  342. [342]

    Galadanci NA, Johnson W, Carson A et al.. “Factors associated with left ventricular hypertrophy in children with sickle cell disease: results from the DISPLACE study.” Haematologica (2022). PMID: 35417940 ↗

    L2OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  343. [343]

    Coates TD, Wood JC. “How we manage iron overload in sickle cell patients.” British journal of haematology (2017). PMID: 28295188 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  344. [344]

    Davila J, O'Brien SH, Mitchell WB et al.. “Evaluating thromboprophylaxis in the sickle cell disease population: Navigating the evidence gap.” British journal of haematology (2024). PMID: 38578212 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 14. Prevention, Screening & Surveillance
  345. [345]

    Hagar W, Vichinsky E. “Advances in clinical research in sickle cell disease.” British journal of haematology (2008). PMID: 18341629 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 12. Prognosis & Natural History
  346. [346]

    Ataga KI, Cappellini MD, Rachmilewitz EA. “Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.” British journal of haematology (2007). PMID: 17854302 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  347. [347]

    Sheth S, Licursi M, Bhatia M. “Sickle cell disease: time for a closer look at treatment options?” British journal of haematology (2013). PMID: 23772687 ↗

    L5REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  348. [348]

    Colombatti R, Maschietto N, Varotto E et al.. “Pulmonary hypertension in sickle cell disease children under 10 years of age.” British journal of haematology (2010). PMID: 20553267 ↗

    L2REVIEW_NARRATIVECited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 14. Prevention, Screening & Surveillance
  349. [349]

    Tutwiler V, Litvinov RI, Protopopova A et al.. “Pathologically stiff erythrocytes impede contraction of blood clots.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34233380 ↗

    L5OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 11. Complications
  350. [350]

    Mehta D. “Case Report: Optimizing ICU management of sickle cell crisis: the impact of bedside ultrasound on clinical decision-making.” Frontiers in medicine (2026). PMID: 42063764 ↗

    L4CASE_REPORTCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  351. [351]

    Sah JA, Twumasi S, Ayirebi AA et al.. “Assessing Liver and Iron Markers in Steady State Pediatric SCD Patients to Ascertain the Hepatic Consequences of Hemotransfusion: A Case-Control Study in Ghana.” Health science reports (2026). PMID: 42022665 ↗

    L3CASE_CONTROLCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  352. [352]

    Nirmal G, Chadha V, Verma S et al.. “Safety, efficacy and feasibility of GCSF and plerixafor based CD34 mobilization for backup autologous stem cell collection in patients undergoing alternate donor hematopoietic stem cell transplant for sickle cell disease: Take away lessons for gene therapy.” Bone marrow transplantation (2026). PMID: 42342967 ↗

    L4OTHERCited in: 10. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
  353. [353]

    Bartolucci P, El Murr T, Roudot-Thoraval F et al.. “A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults.” Blood (2009). PMID: 19717646 ↗

    L1RCTCited in: History and Evolution of Treatment
  354. [354]

    Merlet AN, Messonnier LA, Coudy-Gandilhon C et al.. “Beneficial effects of endurance exercise training on skeletal muscle microvasculature in sickle cell disease patients.” Blood (2019). PMID: 31742587 ↗

    L4RCTCited in: History and Evolution of Treatment
  355. [355]

    Gellen B, Messonnier LA, Galactéros F et al.. “Moderate-intensity endurance-exercise training in patients with sickle-cell disease without severe chronic complications (EXDRE): an open-label randomised controlled trial.” The Lancet. Haematology (2018). PMID: 30389037 ↗

    L1RCTCited in: History and Evolution of Treatment, 11. Complications, 13. Special Populations & Pregnancy
  356. [356]

    Koshy M, Burd L, Wallace D et al.. “Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study.” The New England journal of medicine (1988). PMID: 3054555 ↗

    L1RCTCited in: History and Evolution of Treatment
  357. [357]

    Adams RJ, Brambilla D. “Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.” The New England journal of medicine (2005). PMID: 16382063 ↗

    L1RCTCited in: History and Evolution of Treatment
  358. [358]

    Griffin TC, McIntire D, Buchanan GR. “High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.” The New England journal of medicine (1994). PMID: 8107739 ↗

    L1RCTCited in: History and Evolution of Treatment
  359. [359]

    Wilimas JA, Flynn PM, Harris S et al.. “A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease.” The New England journal of medicine (1993). PMID: 8332152 ↗

    L1RCTCited in: History and Evolution of Treatment
  360. [360]

    Vichinsky EP, Haberkern CM, Neumayr L et al.. “A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group.” The New England journal of medicine (1995). PMID: 7791837 ↗

    L1RCTCited in: History and Evolution of Treatment
  361. [361]

    Xu JZ, Conrey A, Frey I et al.. “A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.” Blood (2022). PMID: 35576529 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  362. [362]

    Walters MC, Patience M, Leisenring W et al.. “Bone marrow transplantation for sickle cell disease.” The New England journal of medicine (1996). PMID: 8663884 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  363. [363]

    Falk RJ, Scheinman J, Phillips G et al.. “Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme.” The New England journal of medicine (1992). PMID: 1542341 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  364. [364]

    Jacobson SJ, Kopecky EA, Joshi P et al.. “Randomised trial of oral morphine for painful episodes of sickle-cell disease in children.” Lancet (London, England) (1997). PMID: 9365450 ↗

    L1RCTCited in: History and Evolution of Treatment
  365. [365]

    De Ceulaer K, Gruber C, Hayes R et al.. “Medroxyprogesterone acetate and homozygous sickle-cell disease.” Lancet (London, England) (1982). PMID: 6178915 ↗

    L1RCTCited in: History and Evolution of Treatment
  366. [366]

    Serjeant GR, de Ceulaer K, Maude GH. “Stilboestrol and stuttering priapism in homozygous sickle-cell disease.” Lancet (London, England) (1985). PMID: 2866338 ↗

    L1RCTCited in: History and Evolution of Treatment
  367. [367]

    Dabis F, Msellati P, Meda N et al.. “6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère-Enfant.” Lancet (London, England) (1999). PMID: 10459959 ↗

    L1RCTCited in: History and Evolution of Treatment
  368. [368]

    de Montalembert M, Bachir D, Hulin A et al.. “Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.” Haematologica (2006). PMID: 17145606 ↗

    L1RCTCited in: History and Evolution of Treatment, 13. Special Populations & Pregnancy
  369. [369]

    de Montalembert M, Brousse V, Elie C et al.. “Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.” Haematologica (2006). PMID: 16434381 ↗

    L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  370. [370]

    Schechter AN. “Hemoglobin research and the origins of molecular medicine.” Blood (2008). PMID: 18988877 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  371. [371]

    Wilber A, Nienhuis AW, Persons DA. “Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities.” Blood (2011). PMID: 21321359 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  372. [372]

    Dembélé AK, Lapoumeroulie C, Diaw M et al.. “Cell-derived microparticles and sickle cell disease chronic vasculopathy in sub-Saharan Africa: A multinational study.” British journal of haematology (2020). PMID: 33249569 ↗

    L3TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  373. [373]

    Vichinsky EP, Lubin BH. “A cautionary note regarding hydroxyurea in sickle cell disease.” Blood (1994). PMID: 7509209 ↗

    L4CASE_REPORTCited in: History and Evolution of Treatment
  374. [374]

    Dutta D, Aujla A, Knoll BM et al.. “Intestinal pathophysiological and microbial changes in sickle cell disease: Potential targets for therapeutic intervention.” British journal of haematology (2019). PMID: 31693163 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  375. [375]

    Kato GJ, Taylor JG. “Pleiotropic effects of intravascular haemolysis on vascular homeostasis.” British journal of haematology (2009). PMID: 19958359 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  376. [376]

    Haverfield EV, McKenzie CA, Forrester T et al.. “UGT1A1 variation and gallstone formation in sickle cell disease.” Blood (2004). PMID: 15388579 ↗

    L2OTHERCited in: History and Evolution of Treatment
  377. [377]

    Platt OS, Thorington BD, Brambilla DJ et al.. “Pain in sickle cell disease. Rates and risk factors.” The New England journal of medicine (1991). PMID: 1710777 ↗

    L2OTHERCited in: History and Evolution of Treatment
  378. [378]

    Saraf SL, Akingbola TS, Shah BN et al.. “Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts.” Blood advances (2017). PMID: 28868518 ↗

    L2OTHERCited in: History and Evolution of Treatment
  379. [379]

    Ghunney WK, Asare EV, Ayete-Nyampong JB et al.. “Most adults with severe HbSC disease are not treated with hydroxyurea.” Blood advances (2023). PMID: 36799926 ↗

    L4OTHERCited in: History and Evolution of Treatment
  380. [380]

    Brandsen RP, Diederen RMH, Bakhlakh S et al.. “Natural history and rate of progression of retinopathy in adult patients with sickle cell disease: an 11-year follow-up study.” Blood advances (2023). PMID: 36897257 ↗

    L2OTHERCited in: History and Evolution of Treatment
  381. [381]

    Christakis J, Vavatsi N, Hassapopoulou H et al.. “Comparison of homozygous sickle cell disease in northern Greece and Jamaica.” Lancet (London, England) (1990). PMID: 1690325 ↗

    L4OTHERCited in: History and Evolution of Treatment
  382. [382]

    Onwubalili JK. “Sickle-cell anaemia: an explanation for the ancient myth of reincarnation in Nigeria.” Lancet (London, England) (1983). PMID: 6136656 ↗

    L5OTHERCited in: History and Evolution of Treatment
  383. [383]

    Shet AS, Lizarralde-Iragorri MA, Naik RP. “The molecular basis for the prothrombotic state in sickle cell disease.” Haematologica (2020). PMID: 33054077 ↗

    L5OTHERCited in: History and Evolution of Treatment
  384. [384]

    van Beers EJ, van Tuijn CF, Mac Gillavry MR et al.. “Sickle cell disease-related organ damage occurs irrespective of pain rate: implications for clinical practice.” Haematologica (2008). PMID: 18367483 ↗

    L2OTHERCited in: History and Evolution of Treatment
  385. [385]

    Odièvre MH, Bony V, Benkerrou M et al.. “Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease.” Haematologica (2008). PMID: 18322255 ↗

    L4OTHERCited in: History and Evolution of Treatment
  386. [386]

    Early ML, Luo A, Solow M et al.. “Natural history of blood pressure in sickle cell disease pregnancy.” British journal of haematology (2023). PMID: 37803527 ↗

    L2OTHERCited in: History and Evolution of Treatment, 13. Special Populations & Pregnancy
  387. [387]

    Manganas K, Delicou S, Xydaki A et al.. “Predisposing factors for advanced liver fibrosis in patients with sickle cell disease.” British journal of haematology (2023). PMID: 37438880 ↗

    L4OTHERCited in: History and Evolution of Treatment
  388. [388]

    Babatunde OO, Bibby MG, Atala A et al.. “Sickle Cell Disease: Historical Overview and Current Therapies.” Prenatal diagnosis (2026). PMID: 42272061 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  389. [389]

    Sharma A, Suryaprakash S, Johnson LM et al.. “Discontinued therapies for sickle cell disease: status and future directions.” Expert opinion on investigational drugs (2026). PMID: 42007797 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  390. [390]

    Ataga KI. “Natural History of Chronic Kidney Disease in Sickle Cell Disease.” American journal of hematology (2026). PMID: 41927315 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  391. [391]

    Therrell BL. “Newborn Screening for Hemoglobinopathies and Thalassemias: Brief History, Recent Activities, and Global Status-2026.” International journal of neonatal screening (2026). PMID: 41718422 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  392. [392]

    Bafunyembaka G, Nacher M, Maniassom C et al.. “Asthma and overt stroke in children with sickle cell disease: a multicenter pediatric cohort study in French Guiana.” BMC pediatrics (2026). PMID: 42387435 ↗

    L2COHORTCited in: History and Evolution of Treatment, 13. Special Populations & Pregnancy
  393. [393]

    Adetoye E, Adebanwo A, Banjo F et al.. “Neurological manifestations in Nigerian children with sickle cell disease: a single-center retrospective study.” BMC pediatrics (2026). PMID: 42337449 ↗

    L4COHORTCited in: History and Evolution of Treatment, 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  394. [394]

    Earley EJ, Kelly S, Fang F et al.. “Genome-wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel loci.” British journal of haematology (2023). PMID: 36602125 ↗

    L3SR_OBSCited in: 11. Complications
  395. [395]

    Ladu AI, Aiyenigba AO, Adekile A et al.. “The spectrum of splenic complications in patients with sickle cell disease in Africa: a systematic review.” British journal of haematology (2020). PMID: 33161568 ↗

    L2SR_OBSCited in: 11. Complications
  396. [396]

    Liu Y, Shayo S, Su S et al.. “Heme-induced activation of the TLR3/TRIF-IFN-I-CCL2 pathway contributes to kidney injury in sickle cell disease.” Blood (2026). PMID: 41481385 ↗

    L5OTHERCited in: 11. Complications
  397. [397]

    Beri D, Rodriguez M, Singh M et al.. “Babesiosis and sickle red blood cells: loss of deformability, altered osmotic fragility, and hypervesiculation.” Blood (2025). PMID: 39869831 ↗

    L5OTHERCited in: 11. Complications
  398. [398]

    Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. “Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.” Blood (2012). PMID: 22563085 ↗

    L5REVIEW_NARRATIVECited in: 11. Complications
  399. [399]

    Kumari N, Nouraie M, Ahmad A et al.. “Restriction of HIV-1 infection in sickle cell trait.” Blood advances (2021). PMID: 34496009 ↗

    L5OTHERCited in: 11. Complications
  400. [400]

    Scourfield LEA, Nardo-Marino A, Williams TN et al.. “Infections in sickle cell disease.” Haematologica (2025). PMID: 39568431 ↗

    L5REVIEW_NARRATIVECited in: 11. Complications, 12. Prognosis & Natural History
  401. [401]

    Brousse V, Buffet P, Rees D. “The spleen and sickle cell disease: the sick(led) spleen.” British journal of haematology (2014). PMID: 24862308 ↗

    L5REVIEW_NARRATIVECited in: 11. Complications
  402. [402]

    O'Hanlon Cohrt K, O'Dea S. “Clinical Trial Landscape of Gene-Edited Autologous Hematopoietic Stem Cells for Hemoglobinopathies and Immunodeficiencies.” International journal of molecular sciences (2026). PMID: 42074029 ↗

    L5TRIAL_NONRANDOMCited in: 11. Complications
  403. [403]

    Malinowski AK, Shehata N, D'Souza R et al.. “Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis.” Blood (2015). PMID: 26302758 ↗

    L1SR_OBSCited in: 12. Prognosis & Natural History, 13. Special Populations & Pregnancy
  404. [404]

    Walters MC, Eapen M, Liu Y et al.. “Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.” Blood advances (2025). PMID: 39471440 ↗

    L2TRIAL_NONRANDOMCited in: 12. Prognosis & Natural History
  405. [405]

    Jiao B, Johnson KM, Ramsey SD et al.. “Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries.” Blood advances (2023). PMID: 36929166 ↗

    L3COHORTCited in: 12. Prognosis & Natural History
  406. [406]

    Ranque B, Kitenge R, Ndiaye DD et al.. “Estimating the risk of child mortality attributable to sickle cell anaemia in sub-Saharan Africa: a retrospective, multicentre, case-control study.” The Lancet. Haematology (2022). PMID: 35240076 ↗

    L3CASE_CONTROLCited in: 12. Prognosis & Natural History, 14. Prevention, Screening & Surveillance
  407. [407]

    Maitra P, Caughey M, Robinson L et al.. “Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.” Haematologica (2017). PMID: 28104703 ↗

    L2SR_OBSCited in: 12. Prognosis & Natural History
  408. [408]

    Stenger EO, Shenoy S, Krishnamurti L. “How I treat sickle cell disease with hematopoietic cell transplantation.” Blood (2019). PMID: 31697818 ↗

    L5CASE_REPORTCited in: 12. Prognosis & Natural History
  409. [409]

    Gardner K, Suddle A, Kane P et al.. “How we treat sickle hepatopathy and liver transplantation in adults.” Blood (2014). PMID: 24565828 ↗

    L5CASE_REPORTCited in: 12. Prognosis & Natural History
  410. [410]

    Tumblin A, Tailor A, Hoehn GT et al.. “Apolipoprotein A-I and serum amyloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease.” Haematologica (2010). PMID: 20378559 ↗

    L4OTHERCited in: 12. Prognosis & Natural History
  411. [411]

    Tubman VN, Makani J. “Turf wars: exploring splenomegaly in sickle cell disease in malaria-endemic regions.” British journal of haematology (2017). PMID: 28493472 ↗

    L5REVIEW_NARRATIVECited in: 12. Prognosis & Natural History
  412. [412]

    Højagergaard MA, Thønnings S, Søes LM et al.. “Antibiotic Treatment Duration for Salmonella Osteoarticular Infections in Children - A Systematic Review and Comparative Study.” Acta paediatrica (Oslo, Norway : 1992) (2026). PMID: 42059540 ↗

    L4SR_OBSCited in: 12. Prognosis & Natural History
  413. [413]

    Ford AL, Ragan DK, Fellah S et al.. “Silent infarcts in sickle cell disease occur in the border zone region and are associated with low cerebral blood flow.” Blood (2018). PMID: 30061156 ↗

    L2RCTCited in: 13. Special Populations & Pregnancy
  414. [414]

    Brothers RO, Turrentine KB, Akbar M et al.. “The influence of voxelotor on cerebral blood flow and oxygen extraction in pediatric sickle cell disease.” Blood (2024). PMID: 38364110 ↗

    L4TRIAL_NONRANDOMCited in: 13. Special Populations & Pregnancy
  415. [415]

    Oteng-Ntim E, Meeks D, Seed PT et al.. “Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis.” Blood (2015). PMID: 25800049 ↗

    L2SR_OBSCited in: 13. Special Populations & Pregnancy
  416. [416]

    Minniti CP, Sable C, Campbell A et al.. “Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation.” Haematologica (2009). PMID: 19211639 ↗

    L4TRIAL_NONRANDOMCited in: 13. Special Populations & Pregnancy
  417. [417]

    Davila J, Stanek J, O'Brien SH. “Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients.” Blood advances (2023). PMID: 37103974 ↗

    L3COHORTCited in: 13. Special Populations & Pregnancy
  418. [418]

    Oakley LL, Mitchell S, von Rege I et al.. “Perinatal outcomes in women with sickle cell disease: a matched cohort study from London, UK.” British journal of haematology (2021). PMID: 34881428 ↗

    L3COHORTCited in: 13. Special Populations & Pregnancy
  419. [419]

    Yuan S, Jordan LC, Davis LT et al.. “A cross-sectional, case-control study of intracranial arterial wall thickness and complete blood count measures in sickle cell disease.” British journal of haematology (2020). PMID: 33326595 ↗

    L3CASE_CONTROLCited in: 13. Special Populations & Pregnancy
  420. [420]

    James AH, Strouse JJ. “How I treat sickle cell disease in pregnancy.” Blood (2024). PMID: 37979134 ↗

    L5OTHERCited in: 13. Special Populations & Pregnancy
  421. [421]

    Schaer DJ, Buehler PW, Alayash AI et al.. “Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins.” Blood (2012). PMID: 23264591 ↗

    L5REVIEW_NARRATIVECited in: 13. Special Populations & Pregnancy
  422. [422]

    van Langevelde K, Flinterman LE, van Hylckama Vlieg A et al.. “Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum.” Blood (2012). PMID: 22496157 ↗

    L3REVIEW_NARRATIVECited in: 13. Special Populations & Pregnancy
  423. [423]

    Guarino SH, Jain A, Madisetti M et al.. “National Alliance of Sickle Cell Centers consensus standards for transition to adult care in sickle cell disease.” Blood advances (2025). PMID: 40472332 ↗

    L5OTHERCited in: 13. Special Populations & Pregnancy
  424. [424]

    Sharma D, Kozanoğlu I, Ataga KI et al.. “Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel.” Blood advances (2024). PMID: 38206762 ↗

    L5OTHERCited in: 13. Special Populations & Pregnancy
  425. [425]

    Colombatti R, Dalla Pozza LV, Mazzucato M et al.. “Hospitalization of children with sickle cell disease in a region with increasing immigration rates.” Haematologica (2008). PMID: 18310539 ↗

    L4OTHERCited in: 13. Special Populations & Pregnancy
  426. [426]

    Bulbul Z, Zareef R, Nassif TA et al.. “Left ventricular strain and chamber dimensions in pediatric sickle cell disease: age-related reduction in myocardial deformation independent of hemolysis and hydroxyurea therapy.” Haematologica (2025). PMID: 41414968 ↗

    L3OTHERCited in: 13. Special Populations & Pregnancy
  427. [427]

    Pecker LH, Sharma D, Nero A et al.. “Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease.” British journal of haematology (2021). PMID: 34231198 ↗

    L5REVIEW_NARRATIVECited in: 13. Special Populations & Pregnancy
  428. [428]

    Sil S, Mooney JT, Adkins TR et al.. “I-STRONG: an integrative, multicomponent treatment approach for chronic pain in pediatric sickle cell disease.” Blood advances (2026). PMID: 42024471 ↗

    L4TRIAL_NONRANDOMCited in: 13. Special Populations & Pregnancy
  429. [429]

    Vilela TS, Fisberg M, Ferrari G et al.. “A systematic review on clinical and laboratory effects of vitamin D deficiency in children with sickle cell disease.” Nutrition and health (2026). PMID: 42339751 ↗

    L2SR_OBSCited in: 13. Special Populations & Pregnancy
  430. [430]

    Field TS, Selvanathan T. “Stroke in Children and Younger Adults.” Continuum (Minneapolis, Minn.) (2026). PMID: 42233825 ↗

    L5CASE_REPORTCited in: 13. Special Populations & Pregnancy
  431. [431]

    Anele UA, Le BV, Resar LM et al.. “How I treat priapism.” Blood (2015). PMID: 25810489 ↗

    L5OTHERCited in: 14. Prevention, Screening & Surveillance
  432. [432]

    Wood JC. “Brain O2 reserve in sickle cell disease.” Blood (2019). PMID: 31147375 ↗

    L5OTHERCited in: 14. Prevention, Screening & Surveillance
  433. [433]

    Ranque B, Menet A, Diop IB et al.. “Early renal damage in patients with sickle cell disease in sub-Saharan Africa: a multinational, prospective, cross-sectional study.” The Lancet. Haematology (2014). PMID: 27030156 ↗

    L4OTHERCited in: 14. Prevention, Screening & Surveillance
  434. [434]

    Green NS, Zapfel A, Nnodu OE et al.. “The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology.” Blood advances (2022). PMID: 36264096 ↗

    L5OTHERCited in: 14. Prevention, Screening & Surveillance
  435. [435]

    Alvarez OA, St Victor Dély N, Paul Hanna M et al.. “Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti.” Blood advances (2024). PMID: 37820110 ↗

    L4OTHERCited in: 14. Prevention, Screening & Surveillance
  436. [436]

    Adamkiewicz TV, Yee MEM, Thomas S et al.. “Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines.” Blood advances (2023). PMID: 37698500 ↗

    L2OTHERCited in: 14. Prevention, Screening & Surveillance
  437. [437]

    Mancini M, Buffet A, Porte B et al.. “EPAS1-mutated paragangliomas associated with haemoglobin disorders.” British journal of haematology (2024). PMID: 38195958 ↗

    L4OTHERCited in: 14. Prevention, Screening & Surveillance
  438. [438]

    Naveed F, Tao BK, Ashamalla M et al.. “Association of hydroxyurea use and sickle cell retinopathy: A systematic review and meta-analysis.” Survey of ophthalmology (2026). PMID: 42242558 ↗

    L2SR_OBSCited in: 14. Prevention, Screening & Surveillance
  439. [439]

    Gangwar M, Kumar G, Roy S et al.. “Study protocol for a randomized, double-blind, placebo-controlled clinical trial of desidustat oral tablet in sickle cell disease: a phase IIa proof-of-concept evaluation.” Trials (2026). PMID: 42106815 ↗

    L5TRIAL_NONRANDOMCited in: 14. Prevention, Screening & Surveillance
  440. [440]

    Abacan MAR, Baltazar-Braganza KR, Cabaluna ITG et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Congenital and Developmental Disorders.” Acta medica Philippina (2026). PMID: 42382931 ↗

    L1GUIDELINECited in: 14. Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…